Stable sunscreen compositions using phenoxazone and phenoxazine compounds
Patent Information
- Application Number
- PCT/US2024/025114
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-04-19
- Filing Date
- 2024-04-18
- Publication Date
- 2024-11-28
AI Technical Summary
Current sunscreens, particularly those containing metal oxides like zinc oxide, face challenges in stability and formulation, leading to inadequate protection against skin damage and aging, and often result in a white cast on the skin.
The development of stable cosmetic compositions incorporating phenoxazone and phenoxazine compounds, such as xanthommatin, encapsulated in liposomes, which provide enhanced UV protection without the white cast, using concentrations that allow for reduced or no mineral sunscreen additives.
These compositions offer improved stability and effectiveness in blocking UV rays, providing a broad spectrum of protection while maintaining skin transparency and improving skin feel, efficacy, and compatibility with other ingredients.
Smart Images

Figure 000001 
Figure 000002 
Figure 000003
Abstract
Description
[0001] STABLE SUNSCREEN COMPOSITIONS USING PHENOXAZONE AND
[0002] PHENOXAZINE COMPOUNDS
[0003] Cross-reference to Related Applications
[0004] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 63 / 460,493 filed on April 19, 2023, the entire teachings of which are incorporated by reference.
[0005] Background
[0006] Skin care can be difficult for a variety of reasons including environmental and genetic factors, with long term consequences of aging, cancer and other indications. Sun exposure is a common cause of short term pain and skin damage, and also cancer and other long term consequences.
[0007] More generally, sun exposure can be blocked or minimized by known sunscreens. But many available sunscreens are not sufficiently protective of the skin to avoid long term skin damage or aging, while others filter the harmful sun rays but leave a white casting on the skin that can be difficult to remove and otherwise undesirable.
[0008] In addition, metal oxides capable of absorbing UVA radiation, such as zinc oxide (ZnO) are among the few UVA sunscreens approved for use in sun protection products. However, their use in sunscreen products has been limited, in part because of the difficulties in formulating them in stable sunscreen compositions. Hence there remains a need to improve the stability of sunscreens with metal oxides, such as ZnO.
[0009] Premature skin aging due to sun exposure or other mechanisms, can be particularly problematic. Intrinsic aging is the natural and chronological physiological decay process that takes place in our body over time. Aging as a consequence of environmental factors, called extrinsic aging, may also contribute to the decay process. Skin undergoes many changes in morphology and physiology with sun exposure, or other intrinsic and / or extrinsic aging mechanisms. As in other organs, skin aging can be accelerated by exposure to environmental factors such as sun and UV radiation, air pollution, dry environment, etc. Skin aging accelerated by environmental factors, called premature or extrinsic aging, can be distinguished from chronological or intrinsic aging by the characteristic signs of each type of aging. Specifically, the signs of extrinsic aging are more pronounced on the skin and include thicker and rougher skin, formation of dark spots and stains, telangiectasia (presence of tiny dilated blood vessels on the skin), sagging and wrinkling of the skin. Changes in the skin morphology and physiology around the eye may include the tissues around the eyes (especially the lower lids), including the muscles, connective tissue, ligaments, orbital septum, and skin supporting the eyelids, weakening. Due to this weakness, normal fat that helps support and encircle the eye balls in the orbital cavity and lower part of the eye ball migrates forward and downwards into the lower eyelids, causing the lids to appear puffy with semicircular swelling and may include wrinkles in the skin and dark circles. Several factors can attribute to these changes including fluid retention due to changes in weather (for example, hot, humid days), changing hormonal levels or eating salty foods, not getting enough sleep, allergies or dermatitis, and heredity factors.
[0010] While medical treatments such as laser treatments, resurfacing or chemical peels, or surgical procedures may be available to treat the above symptoms, there remains a need for additional anti-aging cosmetic compositions that are safe and effective, there also remains a need for improved such formulations that can modulate or block the effects of sun exposure. Summary
[0011] The present application provides cosmetic compositions, and methods of their formulation and use to address the foregoing and other challenges with skin care. Some embodiments comprise cosmetic compositions with a zwitterionic small molecule of molecular weight ranging from 150-600 Da encapsulated in a liposome.
[0012] In certain embodiments, the zwitterionic small molecule comprises a phenoxazone and / or phenoxazine compound, or a salt thereof. In certain embodiments, the phenoxazone and / or phenoxazine compound, or a salt thereof, is selected from xanthommatin, decarboxylated xanthommatin, uncyclized xanthommatin, ommatin D, dihydroxy- xanthommatin, rhodommatin, a derivative of any of the foregoing, a precursor of any of the foregoing, and salts of any of the foregoing.
[0013] In certain embodiments, the phenoxazone and / or phenoxazine compound, or a salt thereof, comprises unaggregated molecules.
[0014] In certain embodiments, the phenoxazone and / or phenoxazine compound, or a salt thereof, is xanthommatin, or a salt thereof. In certain embodiments, the phenoxazone and / or phenoxazine compound, or a salt thereof, is ammonium xanthommatin.
[0015] In certain embodiments, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin), comprises 0.01-5 wt % of the composition.
[0016] In certain embodiments, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin), comprises 0.01-1 wt % of the composition. In certain embodiments, wherein the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin), comprises 0.01-0.4 wt % of the composition.
[0017] In certain embodiments, the cosmetic compositions comprising the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin) is formulated as an antioxidant. Such cosmetic compositions are formulated with a sunscreen. The sunscreen can be a mineral sunscreen or a chemical sunscreen.
[0018] The mineral sunscreen may include one or more of a zinc oxide dispersion, titanium dioxide, or mixtures thereof. The chemical sunscreen may include avobenzone, oxybenzone, oxybenzone cinoxate, homosalate, octisalate, octinoxate, octocrylene, and / or trolamine salicylate.
[0019] In certain embodiments, for example, when using lower concentrations of phenoxazone / phenoxazine compound, or a salt thereof, (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin) for enhanced effect, a mineral sunscreen may be used and could include a zinc oxide dispersion.
[0020] Zinc oxide dispersion can include zinc oxide particles dispersed in a carrier, for example one or more of caprylic / capric triglyceride, polyhydroxystearic acid and stearoyl glutamic acid. In some embodiments, the mineral sunscreen is titanium dioxide.
[0021] In certain embodiments, a cosmetic composition is formulated for application to a region of the skin to provide a sunscreen without leaving a white casting from mineral sunscreen additives when directly applied to the skin.
[0022] Example formulations include low concentrations of phenoxazone / phenoxazine compound, or a salt thereof, (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin) in combination with a mineral sunscreen in a liposome to achieve a given SPF, but at a lower concentration of mineral sunscreen than would ordinarily be needed to achieve the desired SPF based solely on administration of mineral sunscreen (e.g., ZnO).
[0023] In cosmetic compositions of the present application using a liposome, the liposome comprises a phospholipid sac with a liquid (e.g., aqueous) center configured to encapsulate the active ingredient. The liposome may include a polyol.
[0024] In certain embodiments, the phospholipid is selected from natural phospholipids, fatty acids, and synthetic phospholipids. In certain embodiments, the phospholipid comprises one or more of egg yolk lecithin, soybean lecithin, sphingomyelin, hydrogenated or non-hydrogenated phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol, dimyristoylphosphatidylcholine (DMPC), distearoylphosphatidylcholine, palmitoyl-stearoylphosphatidylcholine, dipalmitoyl phosphatidylcholine, and hydrogenated lecithin.
[0025] In certain embodiments, the phospholipid comprises lecithin. In certain embodiments, lecithin is a naturally derived unsaturated or saturated lecithin extracted from soybean or egg yolk. In certain embodiments, the polyol comprises one or more of propanediol, propylene glycol, dipropylene glycol, 1,3-butylene glycol, glycerin, methylpropanediol, isoprene glycol, pentylene glycol, erythritol, xylitol and sorbitol. In certain embodiments, the polyol comprises propanediol.
[0026] In certain embodiments, liposomes used in the cosmetic compositions are less than 1000 nm in diameter. In certain embodiments, the liposomes have a mean diameter of 250 nm. In certain embodiments, the liposomes are from about 200 to about 400 nm in diameter. In certain embodiments, the liposomes have a pH of about 5 to about 8.
[0027] In certain embodiments of the cosmetic compositions of the present application, the composition is a water-in-oil emulsion.
[0028] In certain embodiments of the cosmetic compositions of the present application, the liposomes comprise 1-5 wt % of the composition. In certain embodiments, the liposomes comprise 2-4 wt % of the composition. In certain embodiments, the liposomes comprise 3 wt % of the composition.
[0029] In certain embodiments, the cosmetic compositions of the present application have a pH from about 6.8 to about 7.4. Such compositions may have a Sun Protection Factor (SPF) from about 15 to about 45, and the SPF can vary based on the concentration of the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin). In certain embodiments, the cosmetic composition of the present application is formulated as a lotion, mousse, or a cream. In some embodiments the composition is formulated as a spray.
[0030] In certain embodiments, at sufficiently high concentrations, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin) can also provide a UV filter and therefore can be formulated as a sunscreen that can operate with reduced (or without any) mineral sunscreen or chemical sunscreen additives.
[0031] In certain embodiments, the cosmetic compositions are formulated as sunscreen compositions. Such compositions include a phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin) as the primary active ingredient, optionally with or without the use of a liposome, at a concentration sufficient to allow the composition to filter UV light rays.
[0032] The compositions may include a sufficiently high concentration of the phenoxazone and / or phenoxazine compounds or salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin), so it can function as a sunscreen.
[0033] The phenoxazone / phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin) or a salt thereof is formulated as a UV-filtering material.
[0034] The phenoxazone / phenoxazine compound, or a salt thereof is optionally xanthommatin, decarboxylated xanthommatin, uncyclized xanthommatin, ommatin D, dihydroxy- xanthommatin, rhodommatin, a derivative of any of the foregoing, a precursor of any of the foregoing, and salts of any of the foregoing.
[0035] In certain aspects, the cosmetic compositions, the phenoxazone and / or phenoxazine compound, or a salt thereof is xanthommatin or a salt thereof, wherein the xanthommatin or a salt thereof is ammonium xanthommatin.
[0036] In certain embodiments, the phenoxazone / phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin) as the active ingredient may comprise at least 1 wt % or higher of the cosmetic composition.
[0037] The xanthommatin or a salt thereof may comprise from about 1 wt % to about 5 wt % of the composition.
[0038] In certain embodiments, the cosmetic compositions (e.g., sunscreen formulations) have a pH from about 6.7 to about 8.0. Such compositions may have a Sun Protection Factor (SPF) from about 15 to about 50.
[0039] The Sun Protection Factor (SPF) for such compositions depends on the concentration of the phenoxazone and / or phenoxazine compound, or salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin) in the composition.
[0040] The SPF may be 2-8, or higher, depending on the concentration of the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin).
[0041] The SPF can also be increased by increasing the concentration of the phenoxazone and / or phenoxazine compound, or salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin). For example, the concentration can increase to 1-2%, or 2-5%, or 5-15%, and the SPF can be in the range of about 2 to about 8, 5-10, 10-15, 2-15, 2-20, 15-30 or 15-50, or higher. In certain embodiments, the cosmetic compositions (e.g., sunscreen compositions) are formulated as a cream, mousse, or spray. In certain embodiments, the cosmetic compositions (e.g., sunscreen compositions) of the present application, the composition is water-based or a water-in-oil emulsion.
[0042] In some embodiments, the cosmetic compositions may optionally comprise a liposome, as disclosed herein.
[0043] In certain embodiments, the cosmetic compositions further comprise one or more emollient, one or more emulsifier, diluent, humectant, thickener, pH adjuster and preservative. In some specific embodiments, the compositions comprise one or more UV-filter booster.
[0044] In certain embodiments, the cosmetic compositions may optionally comprise a chelating agent; the chelating agent may be disodium EDTA, for example.
[0045] In certain embodiments, the cosmetic compositions using one or more UV-filter boosters may select the booster from (vegetable oil (and) Simmondsia Chinensis (jojoba) seed oil (and) turmeric root extract), butyl octyl salicylate, or a combination thereof.
[0046] In certain embodiments, the cosmetic compositions comprise one or more emollient, which may be selected from cetearyl nonanoate, caprylic / capric triglyceride, sunflower seed oil, vegetable oil, Simmondsia Chinensis (jojoba) seed oil, Argania Spinosa (argan) oil, curcuma longa (turmeric) root extract, Aloe Barbadensis extract, cetearyl alcohol, cetearyl glucoside, glucose, (vegetable oil (and) Simmondsia Chinensis (jojoba) seed oil (and) turmeric root extract), or a combination thereof.
[0047] In certain embodiments, the cosmetic compositions comprise one or more emulsifier. Emulsifiers may be selected from polysorbate 20, sorbitan olivate, glyceryl stearate SE, polyglyceryl-6 pentaoleate, glyceryl oleate, glyceryl oleate momomuls, olivem 900, oleamuls WO or a combination thereof.
[0048] In certain embodiments, the cosmetic compositions comprise a diluent, for example deionized water.
[0049] In certain embodiments, the cosmetic compositions comprise a humectant. The humectant may include glycerin.
[0050] In certain embodiments, the cosmetic compositions comprise a thickener. The thickener may include xanthum gum.
[0051] In certain embodiments, the cosmetic compositions comprise a preservative. The preservative may include phenoxyethanol (and) ethylhexylglycerin. In certain embodiments, the cosmetic compositions comprise a pH adjuster, such as sodium hydroxide. The present application further provides a method of providing one or more of a sunscreen effect and an effect on one or more signs of skin-aging, comprising applying a cosmetic composition, as described herein, to a region of skin.
[0052] In certain embodiments, the cosmetic composition (formulated, for example, as a sunscreen composition) is applied directly to the region skin. In certain embodiments, the cosmetic composition is applied to the region of skin using a wipe or other solid support. In certain embodiments, the solid support comprises a microfiber based substrate. In certain embodiments, the cosmetic composition is embedded within the microfiber based substrate. In certain embodiments, the wipe is moistened with water prior to applying to the region of skin. In certain embodiments, the solid support is a spray or an anhydrous material.
[0053] In certain embodiments of the methods of the present application, the region of skin comprises skin on one or more of the hands, face, legs, arms, back, stomach, scalp or neck. In certain embodiments, the region of skin comprises skin around an eye. In certain embodiments, the region of skin comprises skin at the corner of an eye. In certain embodiments, the region of skin comprises skin directly above the eye. In certain embodiments, the region of skin comprises skin directly below the eye.
[0054] In certain embodiments of the methods of the present application, the cosmetic composition is removed from the region of the skin after a period of time. In certain embodiments, the cosmetic-composition is removed from the region of the skin 10 minutes following application. In certain embodiments, the combination of the cosmetic composition is removed from the region of the skin 15 minutes following application. In certain embodiments, combination of the cosmetic composition is removed from the region of the skin 20 minutes following application.
[0055] In certain embodiments of the methods of the present application, the effect of the composition on the skin can impact on one or more signs of skin-aging. Such effect may comprise reduction, prevention, or slowing the appearance of puffiness and / or swelling in the region of skin. In certain embodiments, the effect on one or more signs of skin-aging comprises the reduction, elimination, or slowing of the appearance of wrinkles in the region of skin. In certain embodiments, the effect on one or more signs of skin-aging comprises repairing or restoring skin elasticity or firmness in the region of skin. In certain embodiments, the repairing or restoring skin elasticity or firmness comprises stimulating elastin production, stimulating collagen production, and / or stimulating keratin growth in the region of skin. In certain embodiments, the repairing or restoring skin elasticity or firmness comprises stimulating collagen production and / or stimulating keratin growth in the region of skin. In certain embodiments, the effect on one or more signs of skin-aging comprises reducing, preventing, or slowing collagen degradation in the region of skin. In certain embodiments, the effect on one or more signs of skin-aging comprises reduction, prevention, or slowing the appearance of hyperpigmentation in the region of skin.
[0056] In sunscreen applications, methods may include applying one or more compositions as recited herein to a person’s skin to provide UV filter effect and reduce or eliminate the impact of UV rays on the skin.
[0057] Brief Description of the Drawings
[0058] FIG. 1 depicts that when xanthommatin is encapsulated within a liposome, it provides a higher optical density “OD” as compared to unencapsulated xanthommatin or the liposome itself.
[0059] FIG. 2 shows a UV-Vis absorbance spectra of a formulation of liposomes with and without xanthommatin and a formulation with xanthommatin. FIG. 2A shows a UV-Vis absorbance spectrum of a formulation of liposomes with and without addition of xanthommatin compared to blank (without xanthommatin and without liposomes). FIG. 2B shows a UV-Vis absorbance spectrum of xanthommatin only (without liposomes) compared to blank (without xanthommatin).
[0060] FIG. 3 is a UV-Vis transmission spectra of Formulation 3 (0.05% Xa) as a function of wavelength.
[0061] FIG. 4 shows images of petri dishes containing various compositions including a mineral sunscreen. The mineral sunscreen is a zinc oxide dispersion, wherein the zinc oxide particles are dispersed in caprylic / capric triglyceride, polyhydroxystearic acid and stearoyl glutamic acid (32% ZnO). FIG. 4A is an image of Formulation 7 (Control liposome and mineral sunscreen, but without xanthommatin). FIG. 4B is an image of Formulation 6 (0.2 w / w% xanthommatin encapsulated in liposomes and mineral sunscreen). FIG. 4C is an image of Formulation 8 (1 w / w% xanthommatin encapsulated in liposomes and UV-filter boosters, but without mineral sunscreen). FIG. 4D is an image of Formulation 10 (2 w / w% xanthommatin, without UV-filter boosters an liposomes).
[0062] FIG. 5 evaluates the critical wavelength for test products according to broad spectrum testing method published in 21 CFR 201.327 (J). FIG. 5A depicts the in vitro FDA broad spectrum of various compositions. FIG. 5B depicts the in vitro sun protection factor (SPF) of various compositions. FIG. 6 shows the intensity (AU) of Formulation 6 (0.2 w / w% xanthommatin encapsulated in liposomes and mineral sunscreen) and Formulation 7 (Control liposome and mineral sunscreen, but no xanthommatin) at different wavelengths. The mineral sunscreen is a zinc oxide dispersion, wherein the zinc oxide particles are dispersed in caprylic / capric triglyceride, polyhydroxystearic acid and stearoyl glutamic acid (32% ZnO).
[0063] FIG. 7 shows the intensity (AU) of formulations at different wavelength. FIG. 7A shows the intensity of Formulation 8 (1 w / w% xanthommatin encapsulated in liposomes and UV- filter boosters, but without mineral sunscreen) at different wavelength. FIG. 7B shows the intensity of Formulation 10 (2 w / w% xanthommatin, but without UV-filter boosters or liposomes) at different wavelength.
[0064] FIG. 8 shows the in vivo SPF measurements of various formulations in test subjects (n=3).
[0065] FIG. 9 shows an analysis of XA based mineral sunscreens in vitro.
[0066] FIG. 10 shows a white case study with two different skin types.
[0067] FIG. 11 shows UV filter boosting properties of xanthommatin.
[0068] FIG. 12 is a comparison between formulations without xanthommatin, with xanthommatin, and with xanthommatin in liposome.
[0069] Detailed Description
[0070] The present application relates to stable cosmetic compositions comprising a phenoxazone and / or phenoxazine compound, or a salt thereof.
[0071] The phenoxazone and / or phenoxazine compound, or a salt thereof is a zwitterionic small molecule of molecular weight ranging from 150-600 Da, such as 150-500 Da.
[0072] In certain embodiments, the phenoxazone and / or phenoxazine compound, or a salt thereof, is selected from xanthommatin, decarboxylated xanthommatin, uncyclized xanthommatin, ommatin D, dihydroxy -xanthommatin, rhodommatin, a derivative of any of the foregoing, a precursor of any of the foregoing, and salts of any of the foregoing.
[0073] In certain such embodiments, the phenoxazone and / or phenoxazine compound, or a salt thereof, comprises unaggregated molecules.
[0074] In certain embodiments, the phenoxazone and / or phenoxazine compound, or a salt thereof, is xanthommatin, or a salt thereof. In certain embodiments, the xanthommatin, or a salt thereof is ammonium xanthommatin.
[0075] In some specific implementations, the present application also provides a cosmetic composition comprising phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin) that may optionally be encapsulated in a liposome.
[0076] In certain embodiments of the present application, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin), comprises 0.01-5.0 wt % of the cosmetic composition.
[0077] In certain embodiments of the present application, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin), comprises 0.01-1.0 wt % of the cosmetic composition.
[0078] In certain such embodiments, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin), comprises 0.01-0.5 wt %, 0.01-0.4 wt %, 0.01-0.3 wt %, 0.01-0.2 wt %, 0.01-0.1 wt %, 0.05-1.0 wt %, 0.1-1.0 wt %, 0.1-0.9 wt %, 0.1-0.8 wt %, 0.1-0.7 wt %, 0.1-0.6 wt %, 0.1-0.5 wt %, 0.1-0.4 wt %, 0.2-1 wt %, 0.3-1.0 wt %, 0.4-1.0 wt %, 0.5-1.0 wt %, or 0.5-1.0 wt % of the cosmetic composition.
[0079] In certain such embodiments, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin), comprises 0.01-0.4 wt % of the cosmetic composition.
[0080] In certain such embodiments, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin), comprises 0.01-0.5 wt % of the cosmetic composition.
[0081] In certain such embodiments, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin), comprises 0.01-0.1 wt % of the cosmetic composition.
[0082] In certain embodiments, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin) comprises 0.05 wt %, 0.1 wt %, 0.2 wt %, 0.3 wt %, 0.4 wt %, 0.5 wt %, 0.6 wt %, 0.7 wt %, 0.8 wt %, 0.9 wt %, or 1.0 wt % of the composition.
[0083] In certain embodiments, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin), comprises 0.4 wt % of the cosmetic composition.
[0084] In certain embodiments, the cosmetic composition comprises 0.0055-0.55 g of the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin). In certain such embodiments, the cosmetic composition comprises 0.01-0.5 g, 0.05-0.4 g, 0.10-0.30 g, 0.15-0.30, 0.20-0.25, or 0.22 g of the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin).
[0085] The present application provides stable sunscreen compositions comprising a phenoxazone and / or phenoxazine compound, or a salt thereof, wherein the phenoxazone and / or phenoxazine compound, or a salt thereof is formulated as an antioxidant.
[0086] In such aspects, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin), comprises 0.01-0.4 wt % of the cosmetic composition. Such compositions may further comprise a sunscreen, wherein the sunscreen is a mineral sunscreen or a chemical sunscreen.
[0087] The mineral sunscreen can include, but not limited to, a zinc oxide dispersion, titanium dioxide, or mixtures thereof. The chemical sunscreen can include, but not limited to, avobenzone, oxybenzone, oxybenzone cinoxate, homosalate, octisalate, octinoxate, octocrylene, and trolamine salicylate. Such compositions are encapsulated in a liposome.
[0088] In another aspect, the present application also provides stable sunscreen compositions comprising a phenoxazone and / or phenoxazine compound, or a salt thereof, wherein the phenoxazone and / or phenoxazine compound, or a salt thereof act as an efficient UV filtering material.
[0089] In such aspects, the cosmetic compositions comprise at least 1 wt % or higher of phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin).
[0090] Such compositions are formulated as a sunscreen composition without the need for a mineral sunscreen or a chemical sunscreen additive. Such a sunscreen composition may use phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin) as the primary active ingredient at a concentration sufficient to be the active ingredient and act as an efficient UV filtering material. Such cosmetic compositions are also referred to as sunscreen compositions in the present application.
[0091] In such cosmetic compositions, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin) may comprise at least 1 wt % or higher (e.g., 1 wt %, 1.5 wt%, 2 wt %, 1-5 wt %, 5-10 wt % or up to 15 wt %) of the cosmetic composition. In the sunscreen compositions, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin) is formulated as a UV-filtering material.
[0092] Such sunscreen composition may optionally be formulated in a liposome with the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin) encapsulated therein.
[0093] In certain embodiments, the cosmetic compositions described herein is formulated to provide a Sun Protection Factor ("SPF") of at least 2, 5, 8, 10, 15, 30, 60 or 100. In certain embodiments, the composition is formulated to provide a SPF of 15-100. In some aspects, the SPF is from about 15 to about 50 or 75, or even up to 100.
[0094] The Sun Protection Factor for such compositions depends on the concentration of the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin or salt thereof, such as ammonium xanthommatin) in the composition.
[0095] L Liposomal Delivery
[0096] In some implementations, the compositions disclosed herein are formulated in a liposome for delivery to the user’s skin.
[0097] As used herein, the term "liposome" refers to a spherical phospholipid vesicle of colloidal particles associated with themselves and composed of amphiphilic molecules, each having a water soluble head (hydrophilic group) and a water insoluble tail (hydrophobic group), demonstrating a structure aligned by spontaneous binding caused by the interaction between the different groups. The phosopholipid may formulated as a sac with a liquid (e.g., aqueous) center configured to encapsulate the active ingredient.
[0098] In certain embodiments of the cosmetic compositions of the present application, the liposome comprises a phospholipid and a fatty acid, such as a polyol.
[0099] In certain embodiments, the phospholipid is selected from natural phospholipids and synthetic phospholipids.
[0100] In certain embodiments, the phospholipid comprises one or more of egg yolk lecithin, soybean lecithin, sphingomyelin, hydrogenated or non-hydrogenated phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol, dimyristoylphosphatidylcholine (DMPC), distearoylphosphatidylcholine, palmitoylstearoylphosphatidylcholine, dipalmitoyl phosphatidylcholine, and hydrogenated lecithin.
[0101] In certain embodiments, the phospholipid comprises lecithin, such as a naturally derived unsaturated or saturated lecithin extracted from soybean or egg yolk. In certain embodiments, the polyol comprises one or more of propanediol, propylene glycol, dipropylene glycol, 1,3-butylene glycol, glycerin, methylpropanediol, isoprene glycol, pentylene glycol, erythritol, xylitol and sorbitol, such as propanediol.
[0102] In certain embodiments of the cosmetic compositions of the present application, the liposomes are less than 1000 nm in diameter. In certain embodiments of the cosmetic compositions of the present application, the liposomes have a mean diameter of 250 nm. In certain embodiments of the cosmetic compositions of the present application, the liposomes are from about 200 to about 400 nm in diameter.
[0103] In certain embodiments, the liposomes of this size penetrate the stratum corneum and the encapsulated material (e.g., phenoxazone and / or phenoxazine compound, or a salt thereof, such as xanthommatin, or a salt thereof, such as ammonium xanthommatin) is released by diffusion.
[0104] In certain embodiments, the liposomes degrade and deliver the encapsulated material (e.g., phenoxazone and / or phenoxazine compound, or a salt thereof, such as xanthommatin, or a salt thereof, such as ammonium xanthommatin) to the skin.
[0105] In certain embodiments, the encapsulated material (e.g., phenoxazone and / or phenoxazine compound, or a salt thereof, such as xanthommatin, or a salt thereof, such as ammonium xanthommatin) penetrates into deeper layers of the skin compared to the same material without being encapsulated.
[0106] In certain embodiments, more of the encapsulated material (e.g., phenoxazone and / or phenoxazine compound, or a salt thereof, such as xanthommatin, or a salt thereof, such as ammonium xanthommatin) penetrates into the skin as compared to the same material being applied to the skin without being encapsulated.
[0107] In certain embodiments of the cosmetic compositions of the present application, the liposomes have a pH of about 5 to about 8.
[0108] In certain embodiments of the cosmetic compositions of the present application, the liposomes comprise from about 0.1 to about 10 wt % of the composition. In certain embodiments of the cosmetic compositions of the present application, the liposomes comprise from about 1 to about 5 wt % of the composition. In certain embodiments, the liposomes comprise from about 2 to about 4 wt % of the composition. In certain embodiments, the liposomes comprise about 1 wt %, about 2 wt %, about 3 wt %, about 4 wt %, about 5 wt %, about 6 wt % , about 7 wt % , about 8 wt % , about 9 wt % , or about 10 wt % of the composition. In certain embodiments, the liposomes comprise 3 wt % of the composition. Liposomes of the cosmetic compositions of the present application are prepared according to well-known methods. For example, the liposomes encapsulating the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin), can be prepared by simple mixing of the liposome components with the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin). Alternative procedures include extrusions, anti-solvent precipitation, or centrifugation.
[0109] Without wishing to be bound by any theory, it is believed that the liposomes can function as vehicles for the delivery of the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin) through skin barrier in the methods disclosed herein.
[0110] II. Xanthommatin as an Antioxidant
[0111] In a specific aspect of the present application, the cosmetic compositions comprising phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin) is formulated as an antioxidant.
[0112] In such aspects, the cosmetic compositions comprise 0.01-0.4 wt% of phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin).
[0113] In other aspects, the cosmetic compositions comprise 0.01-0.3 wt % of phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin).
[0114] In other aspects, the cosmetic compositions comprise 0.01-0.2 wt % of phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin).
[0115] In other aspects, the cosmetic compositions comprise 0.01-0.1 wt % of phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin).
[0116] In other aspects, the cosmetic compositions comprise 0.01-0.05 wt % of phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin).
[0117] The cosmetic compositions recited herein can further comprise a sunscreen. The sunscreen can be a mineral sunscreen or a chemical sunscreen.
[0118] Non-limiting examples of mineral sunscreen that can be included in the cosmetic compositions include a zinc oxide dispersion, titanium dioxide or mixtures thereof. Non-limiting examples of chemical sunscreen that can be included in the cosmetic compositions include avobenzone, oxybenzone, oxybenzone cinoxate, homosalate, octisalate, octinoxate, octocrylene, and trolamine salicylate.
[0119] In some preferred aspects, the mineral sunscreen is a zinc oxide dispersion, wherein the zinc oxide dispersion comprises zinc oxide particles dispersed in caprylic / capric triglyceride, polyhydroxystearic acid and stearoyl glutamic acid. In some aspects, the mineral sunscreen is titanium dioxide.
[0120] In the cosmetic compositions comprising the mineral sunscreen, the composition is formulated so that the mineral sunscreen does not leave a white cast when applied directly to the skin.
[0121] Without wishing to be bound by any theory, it is considered that cosmetic compositions disclosed herein are stable and efficient to act as a sunscreen and protect the skin from harmful sun rays and aging. These compositions when applied to the skin do not leave a white casting on the skin that can be difficult to remove and otherwise undesirable.
[0122] A problem generally faced in the development of cosmetic compositions and sun care products comprising a mineral sunscreen, such as ZnO is to provide a stable and an effective composition. It is believed that mineral sunscreen compositions precipitate out and can destabilize multicomposite formulations. The problems also arise due to certain properties that metal oxides exhibit in aqueous suspensions.
[0123] The problem is that mineral dispersions tend to aggregate in solution and that these aggregates lead to a decrease in spreadability / flowability. This property can often lead to white caste on skin because the particle size is attributed to increased light scattering.
[0124] Beyond ZnO, TiO2 dispersions have photocatalytic properties, which means that when reacted with sun light, it can generate photoconversion and catalyze electron transfer and can lead to the formation of reactive oxygen species which can accelerate the degradation of organic material and hence lead to formulation instabilities or decreased function.
[0125] Strategies to overcome formulation challenges include: (1) reducing particle size (to nano-scale sizes), and (2) introducing coating / dispersions with oils or silicone on the minerals to aid in miscibility.
[0126] The challenge of working with dispersions is that there is a high oil phase and this can decrease the working volume for active ingredients like phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin) that need a sizeable water phase to aid its stability. The solution provided by the present application is to embed the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin) in liposomes. This aids in stabilizing the disclosed cosmetic formulations with predominate oil phases (like mineral or chemical sunscreens).
[0127] The inclusion of the xanthommatin-liposome in a predominate oil-based formulation enhances protection against photoaging in the cosmetic compositions of the present application. Thus, the cosmetic compositions provide the desired results such as transparency on skin (no white cast), skin feel, efficacy, ease of use and compatibility with other ingredients.
[0128] In certain embodiments, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin), can absorb and scatter a broad range (UV-near IR) of sunlight to provide enhanced activity as a skin protectant.
[0129] In certain embodiments, the cosmetic composition is a water-in-oil emulsion.
[0130] In certain embodiments, the cosmetic compositions formulated as an antioxidant has a pH from about 6.8 to about 7.4. In some aspects, the pH of the cosmetic composition is from about 6.9 to about 7.4. In some aspects, the pH of the cosmetic composition is from about 7.0 to about 7.4. In some aspects, the pH of the cosmetic composition is from about 7.1 to about 7.4. In some aspects, the pH of the cosmetic composition is from about 7.2 to about 7.4. In some aspects, the pH of the cosmetic composition is from about 7.3 to about 7.4.
[0131] In some aspects, the cosmetic compositions formulated as an antioxidant have a SPF from about 15 to about 45. In some aspects, the SPF is from about 15 to about 20. In some aspects, the SPF is from about 15 to about 25. In some aspects, the SPF is from about 15 to about 30. In some aspects, the SPF is from about 15 to about 35.
[0132] In some aspects, the SPF is from about 20 to about 25. In some aspects, the SPF is from about 20 to about 30. In some aspects, the SPF is from about 20 to about 40. In some aspects, the SPF is from about 25 to about 30. In some aspects, the SPF is from about 25 to about 35. In some aspects, the SPF is from about 30 to about 35. In some aspects, the SPF is from about 30 to about 40.
[0133] In certain embodiments, the composition is formulated to provide a UVA protection factor ("UVA-PF") of at least 15, 30, 60, or 100. In certain embodiments, the composition is formulated to provide a UVA-PF of 15-100. In certain embodiments, the composition is formulated to provide a ratio of UVA I to UV filters of at least 0.7 or greater.
[0134] In certain embodiments, the cosmetic compositions of the present application are in the form of a lotion, mousse, or a cream.
[0135] In certain embodiments, the cosmetic compositions may be formulated as a spray. III. Xanthommatin as a UV-Filtering Material
[0136] The present application also evaluates the use of phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin) as a stand-alone UV filtering material in the cosmetic compositions described herein.
[0137] In a specific embodiment, the present application provides a cosmetic composition that is formulated as a sunscreen with a UV filtering material. The UV filtering material comprises phenoxazone and / or phenoxazine compound, or a salt thereof, wherein the phenoxazone and / or phenoxazine compound, or a salt thereof is optionally xanthommatin, decarboxylated xanthommatin, uncyclized xanthommatin, ommatin D, dihydroxy-xanthommatin, rhodommatin, a derivative of any of the foregoing, a precursor of any of the foregoing, and salts of any of the foregoing.
[0138] In such compositions, the phenoxazone and / or phenoxazine compound, or a salt thereof comprise at least 1 wt % or higher of the cosmetic composition.
[0139] In some aspects, the phenoxazine and / or phenoxazine compound, or a salt thereof is xanthommatin or a salt thereof, wherein the xanthommatin or a salt thereof is ammonium xanthommatin.
[0140] In other aspects, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin or a salt thereof, such as ammonium xanthommatin) comprise about 1 wt % of the cosmetic composition.
[0141] In other aspects, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin or a salt thereof, such as ammonium xanthommatin) comprise about 1.5 wt % of the cosmetic composition.
[0142] In other aspects, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin or a salt thereof, such as ammonium xanthommatin) comprise about 2 wt % of the cosmetic composition.
[0143] In specific aspects of the cosmetic composition, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin or a salt thereof, such as ammonium xanthommatin) comprise from about 1 wt % to about 1.5 wt % of the composition.
[0144] In specific aspects of the cosmetic composition, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin or a salt thereof, such as ammonium xanthommatin) comprise from about 1.5 wt % to about 2 wt % of the composition. In specific aspects of the cosmetic composition, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin or a salt thereof, such as ammonium xanthommatin) comprise from about 1 wt % to about 5 wt % of the composition.
[0145] In other aspects, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin or a salt thereof, such as ammonium xanthommatin) comprise from about 1 wt % to about 4 wt % of the cosmetic composition.
[0146] In other aspects, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin or a salt thereof, such as ammonium xanthommatin) comprise from about 1 wt % to about 3 wt % of the cosmetic composition.
[0147] In other aspects, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin or a salt thereof, such as ammonium xanthommatin) comprise from about 1 wt % to about 2 wt % of the cosmetic composition.
[0148] In other aspects, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin or a salt thereof, such as ammonium xanthommatin) comprise from about 2 wt % to about 5 wt % of the cosmetic composition.
[0149] In yet another aspect, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin or a salt thereof, such as ammonium xanthommatin) comprise from about 2 wt % to about 4 wt % of the cosmetic composition.
[0150] In other aspects, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin or a salt, such as ammonium xanthommatin) thereof comprise from about 2 wt % to about 3 wt % of the cosmetic composition.
[0151] In other aspects, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin or a salt thereof, such as ammonium xanthommatin) comprise from about 3 wt % to about 4 wt % of the cosmetic composition.
[0152] In other aspects, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin or a salt thereof, such as ammonium xanthommatin) comprise from about 3 wt % to about 5 wt % of the cosmetic composition.
[0153] In other aspects, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin or a salt thereof, such as ammonium xanthommatin) comprise from about 4 wt % to about 5 wt % of the cosmetic composition.
[0154] In other aspects of the cosmetic composition, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin or a salt thereof, such as ammonium xanthommatin) comprise from about 1 wt % to about 15 wt % of the composition. In other aspects, the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin or a salt thereof, such as ammonium xanthommatin) comprise from about 5 wt % to about 10 wt % of the cosmetic composition.
[0155] In certain aspects, the cosmetic composition formulated as a sunscreen with a UV filtering material has a pH from about 6.7 to about 8.0. In other aspects, the pH of the cosmetic composition is from about 6.8 to about 8.0. In other aspects, the pH of the cosmetic composition is from about 6.9 to about 8.0. In other aspects, the pH of the cosmetic composition is from about 7.0 to about 8.0. In other aspects, the pH of the cosmetic composition is from about 7.1 to about 8.0. In other aspects, the pH of the cosmetic composition is from about 7.2 to about 8.0. In other aspects, the pH of the cosmetic composition is from about 7.3 to about 8.0. In other aspects, the pH of the cosmetic composition is from about 7.4 to about 8.0. In other aspects, the pH of the cosmetic composition is from to about 8.0. In other aspects, the pH of the cosmetic composition is from about 7.6 to about 8.0. In other aspects, the pH of the cosmetic composition is from about 7.7 to about 8.0. In other aspects, the pH of the cosmetic composition is from about 7.8 to about 8.0. In other aspects, the pH of the cosmetic composition is from about 7.9 to about 8.0.
[0156] In certain embodiments, the cosmetic composition formulated as a sunscreen with a UV filtering material have a SPF from about 15 to about 50. In some aspects, the SPF is from about 15 to about 20. In some aspects, the SPF is from about 15 to about 25. In some aspects, the SPF is from about 15 to about 30. In some aspects, the SPF is from about 15 to about 35. In some aspects, the SPF is from about 15 to about 40. In some aspects, the SPF is from about 15 to about 45, or up to about 50 or up to about 75 or 100.
[0157] In some aspects, the SPF is from about 20 to about 25. In some aspects, the SPF is from about 25 to about 30. In some aspects, the SPF is from about 20 to about 30. In some aspects, the SPF is from about 25 to about 35. In some aspects, the SPF is from about 20 to about 35. In some aspects, the SPF is from about 20 to about 40. In some aspects, the SPF is from about 20 to about 45. In some aspects, the SPF is from about 20 to about 50 or up to about 75 or 100.
[0158] In some aspects, the SPF is from about 30 to about 35. In some aspects, the SPF is from about 30 to about 40. In some aspects, the SPF is from about 35 to about 40. In some aspects, the SPF is from about 30 to about 45. In some aspects, the SPF is from about 30 to about 50 or up to about 75 or 100. In some aspects, the SPF is from about 40 to about to about 45. In some aspects, the SPF is from about 40 to about to about 50. In some aspects, the SPF is from about 45 to about 50, or up to about 75 or 100.
[0159] In certain embodiments, the cosmetic compositions of the present application have a SPF from about 2 to about 5 or from about 2 to about 8, or from about 10 to about 25, or from about 15 to about 50.
[0160] The cosmetic compositions of the present application may be formulated as a cream, mousse, or spray.
[0161] The cosmetic compositions may be water-based or a water-in-oil emulsion.
[0162] The cosmetic compositions formulated as a sunscreen with a UV filtering material of the present application may optionally comprise a liposome, for example as disclosed in Section I.
[0163] In some embodiments, a sunscreen composition is disclosed. The composition comprises 32 wt % of zinc oxide dispersion; 0.2 wt % of xanthommatin; 8.2 wt % of an antioxidant carrier; 17 wt % of an emollient; 12 wt % of an emulsifier; 8 wt % of a UV booster; 0.4 wt % of a chelating agent; 4 wt % of a humectant; 0.3 wt % of a thickener; 0.18 wt % of a pH adjuster; and 1.0 wt % of a preservative, wherein the antioxidant carrier comprises propanediol and lecithin.
[0164] In some embodiments, the chelating agent is disodium EDTA.
[0165] In some embodiments, the UV-filter booster is butyl octyl salicylate.
[0166] In some embodiments, the emollient is cetearyl nonanoate, capyrylic / capric triglyceride, sunflower seed oil, vegetable oil, simmondsia chinensis (jojoba) seed oil, and curcuma longa (Turmeric) root extract. In some specific embodiments, the emulsifier is polysorbate 20, sorbitan olivate, glyceryl stearate SE, polyglyceryl-6 pentaoleate, and glyceryl oleate.
[0167] In some embodiments, the humectant is glycerin.
[0168] In some embodiments, the thickener is xanthum gum.
[0169] In some embodiments, the pH adjuster is sodium hydroxide.
[0170] In some embodiments, the preservative is phenoxyethanol and ethylhexylglycerin.
[0171] In one embodiment, a sunscreen composition is disclosed. The sunscreen composition comprises an oil mixture comprising UV booster, UV filter, emollient, and emulsifier; and an aqueous solution comprising diluent, chelating agent, humectant, thickener, antioxidant, antioxidant carrier, and pH adjuster, wherein the antioxidant is a phenoxazone or phenoxazine compound. In some embodiments, the phenoxazone or phenoxazine compound is xanthommatin, decarboxylated xanthommatin, uncyclized xanthommatin, ommatin D, or dihydroxy- xanthommatin, rhodommatin. In some embodiments, the phenoxazone or phenoxazine compound is xanthommatin.
[0172] In some embodiments, the antioxidant comprises about 0.01-0.4 wt % of the sunscreen composition. In some specific embodiments, the antioxidant comprises 0.2 wt % of the sunscreen composition.
[0173] In some embodiments, the UV filter is a zinc oxide dispersion or titanium dioxide. In some embodiments, the UV filter is a zinc oxide dispersion. In some embodiments, the UV filter comprises 25-40 wt % of the sunscreen composition. In some specific embodiments, the UV filter comprises 30-35 wt % of the sunscreen composition. In some more specific embodiments, the UV filter comprises 32 wt % of the sunscreen composition.
[0174] In some embodiments, the antioxidant carrier comprises a phospholipid and a polyol.
[0175] In some embodiments, the phospholipid comprises one or more of egg yolk lecithin, soybean lecithin, sphingomyelin, hydrogenated or non-hydrogenated phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol, dimyristoylphosphatidylcholine (DMPC), distearoylphosphatidylcholine, palmitoylstearoylphosphatidylcholine, dipalmitoyl phosphatidylcholine, and hydrogenated lecithin. In some specific embodiments, the phospholipid is lecithin.
[0176] In some embodiments, the polyol comprises one or more of propanediol, propylene glycol, dipropylene glycol, 1,3-butylene glycol, glycerin, methylpropanediol, isoprene glycol, pentylene glycol, erythritol, xylitol and sorbitol. In some specific embodiments, the polyol comprises propanediol.
[0177] In some embodiments, the antioxidant carrier comprises propanediol and lecithin. In some embodiments, the antioxidant carrier has less than 1000 nm in diameter. In some specific embodiments, the antioxidant carrier has a mean diameter of 250 nm. In some embodiments, the antioxidant carrier has a mean diameter of 250 nm. In some embodiments, the antioxidant carrier comprises 1-10 wt % of the sunscreen composition. In some embodiments, wherein the antioxidant carrier comprises 5-10 wt % of the sunscreen composition. In some embodiments, the antioxidant carrier comprises 8.2 wt % of the sunscreen composition.
[0178] In some embodiments, the chelating agent is disodium EDTA. In some embodiments, the chelating agent comprises 0.2-0.6 wt % of the sunscreen composition. In some embodiments, the chelating agent comprises 0.4 wt % of the sunscreen composition. In some embodiments, the UV-filter booster is butyl octyl salicylate. In some embodiments, the UV-filter booster comprises 5-10 wt % of the sunscreen composition. In some embodiments, the UV-filter booster comprises 8 wt % of the sunscreen composition.
[0179] In some embodiments, the emollient is cetearyl nonanoate, caprylic / capric triglyceride, sunflower seed oil, vegetable oil, Simmondsia Chinensis (jojoba) seed oil, Argania Spinosa (argan) oil, curcuma longa (turmeric) root extract, Aloe Barbadensis extract, cetearyl alcohol, cetearyl glucoside, glucose, (vegetable oil (and) Simmondsia Chinensis (jojoba) seed oil (and) turmeric root extract), or a combination thereof. In some embodiments, the emollient is cetearyl nonanoate, capyrylic / capric triglyceride, sunflower seed oil, vegetable oil, simmondsia chinensis (jojoba) seed oil, and curcuma longa (Turmeric) root extract. In some embodiments, the emollient comprises 10-20 wt % of the sunscreen composition. In some embodiments, the emollient comprises 17 wt % of the sunscreen composition.
[0180] In some embodiments, the emulsifier is polysorbate 20, sorbitan olivate, glyceryl stearate SE, polyglyceryl-6 pentaoleate, glyceryl oleate, glyceryl oleate momomuls, olivem 900, oleamuls WO or a combination thereof. In some embodiments, the emulsifier is polysorbate 20, sorbitan olivate, glyceryl stearate SE, polyglyceryl-6 pentaoleate, and glyceryl oleate. In some embodiments, the emulsifier comprises 5-15 wt % of the sunscreen composition. In some embodiments, the emulsifier comprises 12 wt % of the sunscreen composition.
[0181] In some embodiments, the diluent is deionized water. In some embodiments, the diluent comprises 10-20 wt % of the sunscreen composition. In some embodiments, the diluent comprises 16.72 wt % of the sunscreen composition.
[0182] In some embodiments, the humectant is glycerin. In some embodiments, the humectant comprises 2-7 wt % of the sunscreen composition. In some embodiments, wherein the humectant comprises 4 wt % of the sunscreen composition.
[0183] In some embodiments, the thickener is xanthum gum. In some embodiments, the thickener comprises 0.1-0.5 wt % of the sunscreen composition. In some embodiments, the thickener comprises 0.3 wt % of the sunscreen composition.
[0184] In some embodiments, the pH adjuster is sodium hydroxide. In some embodiments, the pH adjuster comprises 0.1-0.5 wt % of the sunscreen composition. In some embodiments, the pH adjuster comprises 0.18 wt % of the sunscreen composition.
[0185] In some embodiments, the sunscreen composition further comprises a preservative. In some embodiments, the preservative is phenoxyethanol and ethylhexylglycerin. In some embodiments, the preservative comprises 0.5-2.0 wt % of the sunscreen composition. In some embodiments, the preservative comprises 1.0 wt % of the sunscreen composition.
[0186] In some embodiments, the sunscreen composition blocks 30-60 % of a high energy visible light and blue light. In some embodiments, the sunscreen composition blocks 40-50 % of a high energy visible light and blue light. In some embodiments, the sunscreen composition blocks about 45 % of a high energy visible light and blue light. In some embodiments, the sunscreen composition has a Sun Protection Factor (SPF) from about 15 to about 50.
[0187] IV. Other Additives
[0188] In aspects of the present application, _the cosmetic compositions recited in Section II and Section III can further comprise of additives. Such additives, may include, but not limited to one or more UV-filter booster, one or more emollient, one or more emulsifier, a diluent, a humectant, a thickener, a pH adjuster and a preservative.
[0189] In certain embodiments, the cosmetic compositions recited in Section II of the present application can further comprise one or more UV-filter booster, one or more emollient, one or more emulsifier, a diluent, a humectant, a thickener, a pH adjuster and a preservative.
[0190] In certain embodiments, the cosmetic compositions recited in Section III of the present application can further comprise one or more emollient, one or more emulsifier, a diluent, a humectant, a thickener, a pH adjuster and a preservative.
[0191] The cosmetic compositions of the present application may optionally comprise a chelating agent. Such chelating agents may include disodium EDTA and tetrasodium EDTA. In some embodiments, disodium EDTA is the chelating agent.
[0192] The cosmetic compositions of the present application may optionally comprise one or more UV-filter booster. Non-limiting examples of UV-filter booster may include Solapure™ Gio Vegetable Oil (and) Simmondsia Chinensis (jojoba) Seed Oil (and) Curcuma Longa (Turmeric) Root Extract, butyl octyl salicylate, or a combination thereof.
[0193] In certain embodiments, the one or more emollient is selected from cetearyl nonanoate, caprylic / capric triglyceride, sunflower seed oil, vegetable oil, Simmondsia Chinensis (jojoba) seed oil, Argania Spinosa (argan) oil, curcuma longa (turmeric) root extract, Aloe Barbadensis extract, cetearyl alcohol, cetearyl glucoside, glucose, Solapure ™ Gio Vegetable Oil (and) Simmondsia Chinensis (jojoba) Seed Oil (and) Curcuma Longa (Turmeric) Root Extract, or a combination thereof.
[0194] The cosmetic compositions of the present application may further comprise a rheology modifier. In certain embodiments, the rheology modifier is encapsulated in the liposome with the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin). In certain such embodiments, the rheology modifier comprises 0.1-1 wt % of the cosmetic composition. In certain embodiments, the rheology modifier comprises 0.1 wt %, 0.2 wt %, 0.3 wt %, 0.4 wt %, 0.5 wt %, 0.6 wt %, 0.7 wt %, 0.8 wt %, 0.9 wt %, or 1.0 wt % of the cosmetic composition. In certain embodiments, the rheology modifier comprises 0.6 wt % of the cosmetic composition. In certain embodiments, the rheology modifier is present in an amount that prevents significant dripping or pooling of the composition after application to the skin. In certain embodiments, the rheology modifier is carbomer. In some embodiments, the rheology modifier is selected from stearic acid, palmitic acid, stearyl alcohol, cetyl alcohol, behenyl alcohol, stearic acid, palmitic acid, the polyethylene glycol ether of stearyl alcohol having an average of about 1 to about 21 ethylene oxide units, the polyethylene glycol ether of cetyl alcohol having an average of about 1 to about 5 ethylene oxide units, and mixtures thereof.
[0195] Additional examples of rheology modifiers include thickener or gelling agents, including substances which that can increase the viscosity of a composition. Thickening agents include those that can increase the viscosity of a composition without substantially modifying the efficacy of the active ingredient within the composition. Thickening agents can also increase the stability of the compositions of the present invention. In certain aspects of the present invention, thickening agents include hydrogenated polyisobutene or trihydroxy stearin, or a mixture of both. Additional non-limiting examples of additional thickening agents that can be used in the context of the present application include carboxylic acid polymers, crosslinked polyacrylate polymers, polyacrylamide polymers, polysaccharides, and gums. Examples of carboxylic acid polymers include crosslinked compounds containing one or more monomers derived from acrylic acid, substituted acrylic acids, and salts and esters of these acrylic acids and the substituted acrylic acids, wherein the crosslinking agent contains two or more carbon-carbon double bonds and is derived from a polyhydric alcohol (see CTFA International Cosmetic Ingredient Dictionary, Fourth Edition, 1991, pp. 12 and 80). Examples of commercially available carboxylic acid polymers include carbomers, which are homopolymers of acrylic acid crosslinked with allyl ethers of sucrose or pentaerythritol (e.g., Carbopol™ 900 series from B. F. Goodrich). Non-limiting examples of crosslinked polyacrylate polymers include cationic and nonionic polymers.
[0196] Non-limiting examples of polyacrylamide polymers (including nonionic polyacrylamide polymers including substituted branched or unbranched polymers) include polyacrylamide, isoparaffin and Laureth-7, multi-block copolymers of acrylamides and substituted acrylamides with acrylic acids and substituted acrylic acids.
[0197] Non-limiting examples of polysaccharides include cellulose, carboxymethyl hydroxyethylcellulose, cellulose acetate propionate carboxylate, hydroxyethylcellulose, hydroxyethyl ethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methyl hydroxyethylcellulose, microcrystalline cellulose, sodium cellulose sulfate, and mixtures thereof. Another example is an alkyl substituted cellulose where the hydroxy groups of the cellulose polymer are hydroxyalkylated (preferably hydroxy ethylated or hydroxypropylated) to form a hydroxyalkylated cellulose which is then further modified with a C10-C30 straight chain or branched chain alkyl group through an ether linkage. Typically these polymers are ethers of C10-C30 straight or branched chain alcohols with hydroxyalkylcelluloses. Other useful polysaccharides include scleroglucans comprising a linear chain of (1-3) linked glucose units with a (1-6) linked glucose every three unit.
[0198] Non-limiting examples of gums that can be used with the present compositions include acacia, agar, algin, alginic acid, ammonium alginate, amylopectin, calcium alginate, calcium carrageenan, carnitine, carrageenan, dextrin, gelatin, gellan gum, guar gum, guar hydroxypropyltrimonium chloride, hectorite, hyaluroinic acid, hydrated silica, hydroxypropyl chitosan, hydroxypropyl guar, karaya gum, kelp, locust bean gum, natto gum, potassium alginate, potassium carrageenan, propylene glycol alginate, sclerotium gum, sodium carboyxmethyl dextran, sodium carrageenan, tragacanth gum, xanthan gum, and mixtures thereof. In one embodiment, the thickening agent is Chondrus crispus (carrageenan) extract.
[0199] In specific aspects, the cosmetic compositions include xanthum gum as a thickener.
[0200] The cosmetic compositions of the present application may further comprise a moisturizing agent (e.g., humectant). In certain embodiments, the moisturizing agent is encapsulated in the liposome with the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin). In certain such embodiments, the moisturizing agent (e.g., humectant) comprises 0.5-5.0 wt % of the cosmetic composition. In certain embodiments, the moisturizing agent (e.g., humectant) comprises 1.0-5.0 wt % of the cosmetic composition. In certain embodiments, the moisturizing agent (e.g., humectant) comprises 1.5-5.0 wt %, 2.0-5.0 wt %, 2.0-4.0 wt %, 2.5-3.5 wt % , or 3.0-4.0 wt % of the cosmetic composition. In certain embodiments, the moisturizing agent (e.g., humectant) comprises 3.5 wt % of the cosmetic composition. In certain embodiments, the humectant is glycerin. Additional examples of moisturizing agents that can be used with the cosmetic compositions e.g., the sunscreen compositions, of the present invention include amino acids, chondroitin sulfate, diglycerin, erythritol, fructose, glucose, glycerin, glycerol polymers, glycol, 1,2,6-hexanetriol, honey, hyaluronic acid, hydrogenated honey, hydrogenated starch hydroly sate, inositol, lactitol, maltitol, maltose, mannitol, natural moisturizing factor, PEG- 15 butanediol, polyglyceryl sorbitol, salts of pyrollidone carboxylic acid, potassium PCA, propylene glycol, sodium glucuronate, sodium PCA, sorbitol, sucrose, trehalose, urea, and xylitol. In one embodiment, the moisturizing agent is glycerin. Other examples include acetylated lanolin, acetylated lanolin alcohol, alanine, algae extract, aloe barbadensis, aloe- barbadensis extract, aloe barbadensis gel, althea officinalis extract, apricot (prunus armeniaca) kernel oil, arginine, arginine aspartate, arnica montana extract, aspartic acid, avocado (persea gratissima) oil, barrier lipids and sphingolipids (e.g. ceramides), cholesterol and cholesterol esters, butyl alcohol, beeswax, behenyl alcohol, beta-sitosterol, birch (betula alba) bark extract, borage (borago officinalis) extract, butcherbroom (ruscus aculeatus) extract, butylene glycol, calendula officinalis extract, calendula officinalis oil, candelilla (euphorbia cerifera) wax, canola oil, caprylic / capric triglyceride, cardamon (elettaria cardamomum) oil, carnauba (copernicia cerifera) wax, carrot (daucus carota sativa) oil, castor (ricinus communis) oil, ceresin, ceteareth-5, ceteareth-12, ceteareth-20, cetearyl octanoate, ceteth-20, ceteth-24, cetyl acetate, cetyl octanoate, cetyl palmitate, chamomile (anthemis nobilis) oil, cholesterol, cholesterol esters, cholesteryl hydroxystearate, citric acid, clary (salvia sclarea) oil, cocoa (theobroma cacao) butter, coco-caprylate / caprate, coconut (cocos nucifera) oil, collagen, collagen amino acids, corn (zea mays) oil, fatty acids, decyl oleate, dimethicone copolyol, dimethiconol, dioctyl adipate, dioctyl succinate, dipentaerythrityl hexacaprylate / hexacaprate, DNA, erythritol, ethoxydiglycol, ethyl linoleate, eucalyptus globulus oil, evening primrose (oenothera biennis) oil, fatty acids, geranium maculatum oil, glucosamine, glucose glutamate, glutamic acid, glycereth-26, glycerin, glycerol, glyceryl distearate, glyceryl hydroxystearate, glyceryl laurate, glyceryl linoleate, glyceryl myristate, glyceryl oleate, glyceryl stearate, glyceryl stearate SE, glycine, glycol stearate, glycol stearate SE, glycosaminoglycans, grape (vitis vinifera) seed oil, hazel (corylus americana) nut oil, hazel (corylus avellana) nut oil, hexylene glycol, hyaluronic acid, hybrid safflower (carthamus tinctorius) oil, hydrogenated castor oil, hydrogenated coco-glycerides, hydrogenated coconut oil, hydrogenated lanolin, hydrogenated lecithin, hydrogenated palm glyceride, hydrogenated palm kernel oil, hydrogenated soybean oil, hydrogenated tallow glyceride, hydrogenated vegetable oil, hydrolyzed collagen, hydrolyzed elastin, hydrolyzed glycosaminoglycans, hydrolyzed keratin, hydrolyzed soy protein, hydroxylated lanolin, hydroxyproline, isocetyl stearate, isocetyl stearoyl stearate, isodecyl oleate, isopropyl isostearate, isopropyl lanolate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, isostearamide DEA, isostearic acid, isostearyl lactate, isostearyl neopentanoate, jasmine (jasminum officinale) oil, jojoba (buxus chinensis) oil, kelp, kukui (aleurites moluccana) nut oil, lactamide MEA, laneth-16, laneth-10 acetate, lanolin, lanolin acid, lanolin alcohol, lanolin oil, lanolin wax, lavender (lavandula angustifolia) oil, lecithin, lemon (citrus medica limonum) oil, linoleic acid, linolenic acid, macadamia ternifolia nut oil, maltitol, matricaria (chamomilla recutita) oil, methyl glucose sesqui stearate, methylsilanol PCA, mineral oil, mink oil, mortierella oil, myristyl lactate, myristyl myristate, myristyl propionate, neopentyl glycol dicaprylate / dicaprate, octyl dodecanol, octyldodecyl myristate, octyldodecyl stearoyl stearate, octyl hydroxystearate, octyl palmitate, octyl salicylate, octyl stearate, oleic acid, olive (olea europaea) oil, orange (citrus aurantium dulcis) oil, palm (elaeis guineensis) oil, palmitic acid, pantethine, panthenol, panthenyl ethyl ether, paraffin, PCA, peach (prunus persica) kernel oil, peanut (arachis hypogaea) oil. Additional non-limiting examples of moisturizing agents may include PEG-8 C12-18 ester, PEG-15 cocamine, PEG-150 distearate, PEG-60 glyceryl isostearate, PEG-5 glyceryl stearate, PEG-30 glyceryl stearate, PEG-7 hydrogenated castor oil, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-20 methyl glucose sesqui stearate, PEG40 sorbitan peroleate, PEG-5 soy sterol, PEG- 10 soy sterol, PEG-2 stearate, PEG-8 stearate, PEG-20 stearate, PEG- 32 stearate, PEG40 stearate, PEG-50 stearate, PEG-100 stearate, PEG-150 stearate, pentadecalactone, peppermint (mentha piperita) oil, petrolatum, phospholipids, polyamino sugar condensate, polyglyceryl-3 diisostearate, polyquatemium-24, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polysorbate 85, potassium myristate, potassium palmitate, propylene glycol, propylene glycol dicaprylate / dicaprate, propylene glycol dioctanoate, propylene glycol dipelargonate, propylene glycol laurate, propylene glycol stearate, propylene glycol stearate SE, PVP, pyridoxine dipalmitate, retinol, retinol palmitate, rice (oryza sativa) bran oil, RNA, rosemary (rosmarinus officinalis) oil, rose oil, safflower (carthamus tinctorius) oil, sage (salvia officinalis) oil, sandalwood (santalum album) oil, serine, serum protein, sesame (sesamum indicum) oil, shea butter (butyrospermum parkii), silk powder, sodium chondroitin sulfate, sodium hyaluronate, sodium lactate, sodium palmitate, sodium PCA, sodium polyglutamate, soluble collagen, sorbitan laurate, sorbitan oleate, sorbitan palmitate, sorbitan sesqui oleate, sorbitan stearate, sorbitol, soybean (glycine soja) oil, sphingolipids, squalane, squalene, stearamide MEA-stearate, stearic acid, stearoxy dimethicone, stearoxytrimethylsilane, stearyl alcohol, stearyl glycyrrhetinate, stearyl heptanoate, stearyl stearate, sunflower (helianthus annuus) seed oil, sweet almond (prunus amygdalus dulcis) oil, synthetic beeswax, tocopherol, tocopheryl acetate, tocopheryl linoleate, tribehenin, tridecyl neopentanoate, tridecyl stearate, triethanolamine, tristearin, urea, vegetable oil, water, waxes, wheat (trificum vulgare) germ oil, and ylang (cananga odorata) oil. In one embodiment, the moisturizing agent may be allantoin.
[0201] The cosmetic compositions of the present application may further comprise a preservative. In certain embodiments, the preservative is encapsulated in the liposome with the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin). In certain such embodiments, the preservative comprises 0.1-2 wt % of the cosmetic composition. In certain such embodiments, the preservative comprises 0.1-1 wt % of the cosmetic composition. In certain such embodiments, the preservative comprises 0.5-1 wt % of the cosmetic composition. In certain embodiments, the preservative comprises 0.65 wt %, 0.7 wt %, 0.75 wt %, 0.8 wt %, 0.85 wt %, 0.9 wt %, or 1.0 wt % of the cosmetic composition. In certain embodiments, the preservative comprises 0.95 wt % of the cosmetic composition. In certain embodiments, the preservative is phenoxyethanol. In certain embodiments, the preservative is selected from one or more of quaternary ammonium preservatives such as polyquaternium-1 and benzalkonium halides (e.g., benzalkonium chloride (“BAC”) and benzalkonium bromide), parabens (e.g., methylparabens and propylparabens), phenoxyethanol, ethylhexylglycerin, ethylhexylglycerinbenzyl alcohol, chlorobutanol, phenol, sorbic acid, thimerosal and combinations thereof.
[0202] In specific aspects, the cosmetic compositions comprise phenoxyethanol (and) ethylhexylglycerin (Euxyl®PE 9010) as the preservative.
[0203] The cosmetic compositions of the present application may further comprise a pH adjuster. In certain embodiments, the pH adjuster is encapsulated in the liposome with the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin). In certain such embodiments, the pH adjuster comprises 0.1-1 wt % of the cosmetic composition. In certain embodiments, the pH adjuster comprises 0.1 wt %, 0.2 wt %, 0.3 wt %, 0.4 wt %, 0.5 wt %, 0.6 wt %, 0.7 wt %, 0.8 wt %, 0.9 wt %, or 1.0 wt % of the cosmetic composition. In certain embodiments, the pH adjuster comprises 0.4 wt % of the cosmetic composition. In certain embodiments, the pH adjuster is sodium hydroxide.
[0204] The cosmetic compositions of the present application may further comprise excipients commonly used in the formulation of cosmetic or pharmaceutical preparations for topical use, such as bactericidal agents, stabilizers, emulsifiers, buffers, wetting agents, coloring agents, and other excipients commonly used in the cosmetic / pharmaceutical preparation techniques.
[0205] The cosmetic compositions of the present application may comprise one or more emulsifiers. In certain such embodiments, the emulsifier reduces the interfacial tension between phases and improves the formulation and stability of an emulsion. The emulsifier may include a non-ionic emulsifier, an anionic emulsifier, a cationic emulsifier, a Zwitterionic emulsifier or a combination thereof. Non-limiting examples of emulsifiers include esters of glycerin, esters of propylene glycol, fatty acid esters of polyethylene glycol, fatty acid esters of polypropylene glycol, esters of sorbitol, esters of sorbitan anhydrides, carboxylic acid copolymers, esters and ethers of glucose, ethoxylated ethers, ethoxylated alcohols, alkyl phosphates, polyoxyethylene fatty ether phosphates, fatty acid amides, acyl lactylates, soaps, TEA stearate, DEA oleth-3 phosphate, polyethylene glycol 20 sorbitan monolaurate (polysorbate 20), polyethylene glycol 5 soya sterol, Steareth-2, Steareth-20, Steareth-21, ceteareth-20. PPG-2 methylglucose ether distearate, ceteth 10, polysorbate 80, cetyl phosphate, potassium cetyl phosphate, diethanolamine cetyl phosphate, polysorbate 60, glyceryl Stearate, PEG- 100 stearate, and mixtures thereof. In one embodiment, the non-ionic emulsifier is cetearyl olivate or sorbitan olivate.
[0206] In some aspects, the cosmetic compositions comprise one or more emulsifiers selected from polysorbate 20, sorbitan olivate, glyceryl stearate SE, polyglyceryl-6 pentaoleate, glyceryl oleate, glyceryl oleate momomuls, olivem 900, oleamuls WO or a combination thereof.
[0207] The cosmetic compositions of the present application may include a diluent. The diluent is added for the purpose of decreasing formulation viscosity. Non-limiting examples of a diluent include solvents such as water or some low viscosity oils (e.g., sunflower seed oil or vegetable oils). In specific aspects, the cosmetic compositions, e.g., the sunscreen compositions, of the invention comprise deionized water as the diluent.
[0208] In certain embodiments, the cosmetic compositions, e.g., the sunscreen compositions, of the present application are combined with one or more further cosmetic ingredients and / or compositions prior to use. In certain embodiments, the cosmetic compositions of the present application are combined with one or more further cosmetic ingredients and / or compositions in a standard daily skin regime, such as comprising part of a cleanser, toner, serum, moisturizer, or the like. In certain embodiments, the one or more further cosmetic ingredients and / or compositions are encapsulated in the liposome with the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin).
[0209] In certain embodiments of the present application wherein the cosmetic composition, e.g., the sunscreen compositions, is combined with one or more further cosmetic ingredients and / or compositions prior to use, the one or more further cosmetic ingredients and / or compositions comprises one or more moisturizing agent, surfactant, UV absorbing agent, UV scattering agent, fragrance, anti-oxidant, preservative, body pigment, color pigments pH adjusting agent, solvent or any other suitable general cosmetic or topical dermatologic drug ingredient.
[0210] In certain embodiments of the present application wherein the cosmetic composition, e.g., the sunscreen compositions, is combined with one or more further cosmetic ingredients and / or compositions prior to use, the one or more further cosmetic ingredients and / or compositions comprises one or more UV absorbing or UV scattering agent. In certain such embodiments, the one or more UV-absorbing agent is selected from avobenzone, oxybenzone, oxybenzone cinoxate, homosalate, octisalate, octinoxate, octocrylene, and trolamine salicylate, bemotrizinol, and bisoctrizole. In certain embodiments, the UV-absorbing agent includes chemical and physical sunblocks. Non-limiting examples of chemical sunblocks that can be used include bemotrizinol (Tinosorb S), bisoctrizole (Tinosorb M), para-aminobenzoic acid (PABA), PAB A esters (glyceryl PAB A, amyldimethyl PAB A and octyldimethyl PABA), butyl PABA, ethyl PABA, ethyl dihydroxypropyl PABA, benzophenones (oxybenzone, sulisobenzone, benzophenone, and benzophenone- 1 through 12), cinnamates (octyl methoxy cinnamate, isoamyl p-methoxy cinnamate, octylmethoxy cinnamate, cinoxate, diisopropyl methyl cinnamate, DEA-methoxycinnamate, ethyl diisopropylcinnamate, glyceryl octanoate dimethoxycinnamate and ethyl methoxycinnamate), cinnamate esters, salicylates (homomethyl salicylate, benzyl salicylate, glycol salicylate, isopropylbenzyl salicylate, etc.), anthranilates, ethyl urocanate, homosalate, octisalate, dibenzoylmethane derivatives (e.g., avobenzone), octocrylene, octyl triazone, digalloy trioleate, glyceryl aminobenzoate, lawsone with dihydroxyacetone, ethylhexyl triazone, dioctyl butamido triazone, benzylidene malonate polysiloxane, terephthalylidene dicamphor sulfonic acid, disodium phenyl dibenzimidazole tetrasulfonate, diethylamino hydroxybenzoyl hexyl benzoate, bis diethylamino hydroxybenzoyl benzoate, bis benzoxazoylphenyl ethylhexylimino triazine, drometrizole trisiloxane, methylene bis-benzotriazolyl tetramethylbutylphenol, and bisethylhexyloxyphenol methoxyphenyltriazine, 4-methylbenzylidenecamphor, and isopentyl 4- methoxycinnamate. Non-limiting examples of physical sunblocks include kaolin, talc, petrolatum and metal oxides (e.g., titanium dioxide and zinc oxide).
[0211] In certain embodiments of the present application wherein the cosmetic composition, e.g., the sunscreen composition, is combined with one or more further cosmetic ingredients and / or compositions prior to use, the one or more further cosmetic ingredients and / or compositions comprises one or more antioxidant. Non-limiting examples of antioxidants that can be used with the compositions of the present invention include acetyl cysteine, alpha-lipoic acid, arbutin, ascorbic acid, ascorbic acid polypeptide, ascorbyl dipalmitate, ascorbyl methylsilanol pectinate, ascorbyl palmitate, ascorbyl stearate, BHA, BHT, t-butyl hydroquinone, caffeic acid, carotenoids, chlorogenic acid, cysteine, cysteine HC1, diamyihydroquinone, di-t-butylhydroquinone, dicetyl thiodipropionate, dioleyl tocopheryl methylsilanol, disodium ascorbyl sulfate, distearyl thiodipropionate, ditridecyl thiodipropionate, dodecyl gallate, erythorbic acid, esters of ascorbic acid, ethyl ferulate, ferulic acid, flavone, flavanone, flavanol, gallic acid esters, glutathione, goosypol, hydroquinone, hydroxyanisole, isoflavones, isooctyl thioglycolate, ithiothreitol, kojic acid, magnesium ascorbate, magnesium ascorbyl phosphate, methylsilanol ascorbate, natural botanical antioxidants such as green tea or grape seed extracts, nordihydroguaiaretic acid, octyl gallate, phenylthioglycolic acid, potassium ascorbyl tocopheryl phosphate, potassium sulfite, propyl gallate, protocatechuic acid, quinones, rosmarinic acid, sodium ascorbate, sodium bisulfite, sodium erythorbate, sodium metabisulfite, sodium sulfite, superoxide dismutase, sodium thioglycolate, sorbityl furfural, thiodiglycol, thiodiglycolamide, thiodiglycolic acid, thiodipropionic acid, thioglycolic acid, thiolactic acid, thiosalicylic acid, tocophereth-5, tocophereth-10, tocophereth-12, tocophereth-18, tocophereth-50, tocopherol, tocophersolan, tocopheryl acetate, tocopheryl linoleate, tocopheryl nicotinate, tocopheryl succinate, tris(nonylphenyl)phosphite, Trolox, vanillic acid (and its derivatives) and xanthines, including methylxanthines (e.g., caffeine).
[0212] In certain embodiments of the present application wherein the cosmetic composition, e.g., the sunscreen composition, is combined with one or more further cosmetic ingredients and / or compositions prior to use, the one or more further cosmetic ingredients and / or compositions comprises one or more agent selected from alpha and beta hydroxy acids, amino acids, peptides, matrix proteins, growth factors, stem cell activators, estrogens, anti-androgens, and skin lightening and brightening agents.
[0213] In certain embodiments of the present application wherein the cosmetic composition, e.g., the sunscreen composition, is combined with one or more further cosmetic ingredients and / or compositions prior to use, the one or more further cosmetic ingredients and / or compositions comprises one or more cosmetic ingredient. A wide variety of non-limiting cosmetic ingredients described in the CTFA International Cosmetic Ingredient Dictionary and Handbook (2004 and 2008) can be used. Non-limiting examples of cosmetic ingredients include fragrances (artificial and natural), dyes and color ingredients (e.g., Blue 1, Blue 1 Lake, Red 40, titanium dioxide, D&C blue no. 4, D&C green no. 5, D&C orange no. 4, D&C red no. 17, D&C red no. 33, D&C violet no. 2, D&C yellow no. 10, and D&C yellow no. 11), adsorbents, lubricants, solvents, moisturizers (including, e.g., emollients, humectants, film formers, occlusive agents, and agents that affect the natural moisturization mechanisms of the skin), water-repellants, UV absorbers (physical and chemical absorbers such as paraminobenzoic acid (“PABA”) and corresponding PABA derivatives, titanium dioxide, zinc oxide, etc.), essential oils, vitamins (e.g., A, B, C, D, E, and K), trace metals (e.g. zinc, calcium and selenium), anti-irritants (e.g. steroids and non-steroidal anti-inflammatories), botanical extracts (e.g. aloe vera, chamomile, cucumber extract, ginkgo biloba, ginseng, and rosemary), anti-microbial agents, antioxidants (e.g., BHT and tocopherol), chelating agents (e.g., disodium EDTA and tetrasodium EDTA), preservatives (e.g., methylparaben and propylparaben), pH adjusters (e.g., sodium hydroxide and citric acid), absorbents (e.g., aluminum starch octenyl succinate, kaolin, corn starch, oat starch, cyclodextrin, talc, and zeolite), skin bleaching and lightening agents (e.g., hydroquinone and niacinamide lactate), humectants (e.g., sorbitol, urea, and manitol), exfoliants, waterproofing agents (e.g., magnesium / aluminum hydroxide stearate), skin conditioning agents (e.g., aloe extracts, allantoin, bisabolol, ceramides, dimethicone, hyaluronic acid, and dipotassium glycyrrhizate).
[0214] In certain embodiments of the present application, the cosmetic composition, e.g., the sunscreen composition, is combined with one or more topical dermatologic drug composition prior to use. In certain such embodiments, the pharmaceutically active agent is selected from anti-acne agents, agents used to treat rosacea, analgesics, anesthetics, anorectals, antihistamines, anti-inflammatory agents including non-steroidal anti-inflammatory drugs, antibiotics, antifungals, antivirals, antimicrobials, anti-cancer actives, scabicides, pediculicides, antineoplastics, antiperspirants, antipruritics, antipsoriatic agents, antiseborrheic agents, biologically active proteins and peptides, burn treatment agents, cauterizing agents, depigmenting agents, depilatories, diaper rash treatment agents, enzymes, hair growth stimulants, hair growth retardants including eflornithine and its salts and analogs, hemostatics, kerotolytics, canker sore treatment agents, cold sore treatment agents, dental and periodontal treatment agents, photosensitizing actives, skin protectant / barrier agents, steroids including hormones and corticosteroids, sunburn treatment agents, sunscreens, transdermal actives, nasal actives, vaginal actives, wart treatment agents, wound treatment agents, wound healing agents, etc.
[0215] In certain embodiments of the present application wherein the cosmetic composition, e.g., the sunscreen composition, is combined with a further cosmetic composition or topical dermatologic drug composition prior to use, the final composition is applied to the affected skin area one or more time per day. In certain embodiments of the present application wherein the cosmetic composition, e.g., the sunscreen composition, is combined with a further cosmetic composition or topical dermatologic drug composition prior to use, the final composition is applied to the affected skin area one or more time per week.
[0216] In certain embodiments of the cosmetic compositions, e.g., the sunscreen composition, of the present application, the cosmetic composition is in the form of a gel or liquid. In certain such embodiments, the cosmetic composition is in the form of a gel. In certain embodiments of the present application wherein the cosmetic composition is combined with a further cosmetic composition or topical dermatologic drug composition prior to use, the final composition is in the form of a lotion, a mousse, a cream, a gel (e.g., a hydrogel), an emulsion (e.g., oil-in-water, water-in-oil, silicone-in water, water-in-silicone, water-in-oil-in-water, oilin-water-in-oil, oil-in-water-in-silicone, etc.), solutions (e.g., aqueous or hydro-alcoholic solutions), anhydrous bases (e.g., lipstick or a powder), ointments, milk, paste, aerosol, foam, mousse, solid forms, eye jellies, or powdered form (e.g., dried, lyophilized, particulate, etc.). In certain embodiments of the cosmetic compositions of the present application, the cosmetic composition comprises one or more performance enhancing delivery vehicles, such as liposomes, microsponges, silica matrices, and / or any suitable performance enhancing delivery vehicle.
[0217] In certain embodiments of the methods of the cosmetic compositions, e.g., the sunscreen composition, of the present application, the subject is a human subject.
[0218] V. Methods
[0219] The present invention provides a method of providing an effect on one or more signs of skin-aging, comprising applying to a region of skin a cosmetic composition, such as the sunscreen composition, as disclosed herein.
[0220] In certain embodiments of the methods of the present application, the cosmetic composition (e.g., the sunscreen composition implementation) is applied directly to the region of the skin. In certain embodiments of the methods of the present application, the cosmetic composition is applied to a region of skin using a wipe or other solid support. In certain embodiments, the wipe or other solid support comprises a microfiber based substrate. In certain such embodiments, the microfiber based substrate is dehydrated. In certain embodiments, the cosmetic composition is embedded within the microfiber based substrate, such as physically entangled within a fibrous polymer matrix. In certain embodiments, the cosmetic composition is embedded within the microfiber based substrate by drop-casting a solution comprising liposomes encapsulating the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin) onto the microfibers. In certain embodiments, the cosmetic composition is embedded within the microfiber based substrate by soaking the microfibers in a solution comprising liposomes encapsulating the phenoxazone and / or phenoxazine compound, or a salt thereof (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin).
[0221] In certain embodiments due to the nanostructure geometry of the liposomes, the liposomes wick into the fibers or are physically trapped within and between the individual microfiber pores as the solvent is evaporated. In certain embodiments, the wipe is moistened with water prior to applying to the region of skin. In certain such embodiments, the liposome is released from the microfiber based substrate upon addition of the water.
[0222] In certain embodiments, the microfiber based substrate is free of preservatives, emollients, humectants, and fragrances. Examples of microfiber based substrates are those as described by Filabe. See, for example, U.S. Patent No. 10,603,253 for suitable microfiber based substrates.
[0223] In certain embodiments of the methods of the present application, the solid support is a spray or an anhydrous material, such as but not limited to a sunscreen stick.
[0224] In certain embodiments of the methods of the present application, the region of skin comprises skin on one or more of the hands, legs, arms, back, stomach, scalp, face or neck.
[0225] In certain embodiments of the methods of the present application, the region of skin comprises skin around an eye. In certain embodiments, the region of skin comprises skin around an eye. In certain embodiments, the region of skin comprises skin at the corner of an eye. In certain embodiments, the region of skin comprises skin directly above the eye. In certain embodiments, the region of skin comprises skin directly below the eye.
[0226] In certain embodiments of the methods disclosed herein, the cosmetic composition, e.g., the sunscreen composition, is applied to the skin one or more times per day, such as one time per day. In certain embodiments of the methods disclosed herein, the cosmetic composition is applied to the skin one or more times per week, such as one time per week.
[0227] In certain embodiments of the methods disclosed herein, the cosmetic composition, e.g., the sunscreen composition, is removed from the region of the skin after a period of time. In certain such embodiments, the cosmetic composition is removed from the region of the skin by wiping or peeling the combination from the skin. In certain embodiments, cosmetic composition is removed from the region of the skin about 1-30 minutes following application, such as about 5-30, 10-30, 10-25, 10-20, 10-15, 15-20, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 minutes following application. In certain embodiments, the cosmetic composition is removed from the region of the skin about 10 minutes following application. In certain embodiments, the cosmetic composition is removed from the region of the skin about 15 minutes following application. In certain embodiments, the cosmetic composition is removed from the region of the skin about 20 minutes following application.
[0228] In certain embodiments of the methods disclosed herein, the effect on one or more signs of skin-aging comprises reduction, prevention, or slowing the appearance of puffiness and / or swelling in the region of skin.
[0229] In certain embodiments of the methods disclosed herein, the effect on one or more signs of skin-aging comprises the reduction, elimination, or slowing of the appearance of wrinkles in the region of skin.
[0230] In certain embodiments of the methods disclosed herein, the effect on one or more signs of skin-aging comprises repairing or restoring skin elasticity or firmness in the region of skin. In certain such embodiments, the repairing or restoring skin elasticity or firmness comprises stimulating elastin, stimulating collagen, and / or stimulating keratin growth production in the region of skin.
[0231] In certain embodiments of the methods disclosed herein, the effect on one or more signs of skin-aging comprises reducing, preventing, or slowing collagen degradation in the region of skin.
[0232] In certain embodiments of the methods disclosed herein, wherein the effect on one or more signs of skin-aging comprises reduction, prevention, or slowing the appearance of hyperpigmentation in the region of skin.
[0233] In certain embodiments, the effect on one or more signs of skin-aging comprises the reduction, elimination, or slowing of the appearance of wrinkles. In certain such embodiments, the cosmetic compositions of the present application reduce, eliminate, or slow the appearance of wrinkles through the increased production of elastin, keratin, and / or collagen. In other embodiments, the effect on one or more signs of skin-aging comprises repairing or restoring skin elasticity or firmness. In certain such embodiments, the cosmetic compositions of the present application repair or restore skin elasticity or firmness through the increased production of elastin, keratin, and / or collagen.
[0234] In still further embodiments, the effect on one or more signs of skin-aging comprises reduction, prevention, or slowing the appearance of hyperpigmentation. In certain embodiments, the hyperpigmentation is a result of increased melanin production which produces dark spots (e.g., age spots or freckles) on the skin, such as on the hands and / or face. In certain embodiments, the effect on one or more signs of skin-aging comprises the reduction, slowing or elimination of benign dysplasias and / or precancers.
[0235] In certain embodiments, signs of skin aging include, but are not limited to, outward visibly and tactilely perceptible manifestations as well as macro or micro effects due to skin aging. These signs may result from processes which include, but are not limited to, the development of textural discontinuities such as wrinkles and coarse deep wrinkles, fine lines, skin lines, crevices, bumps, large pores (e.g., associated with adnexal structures such as sweat gland ducts, sebaceous glands, or hair follicles), or unevenness or roughness, loss of skin elasticity (loss and / or inactivation of functional skin elastin), sagging (including puffiness in the eye area and jowls), loss of skin firmness, loss of skin tightness, loss of skin recoil from deformation, discoloration (including under eye circles), blotching, sallowness, hyperpigmented skin regions such as age spots and freckles, keratoses, abnormal differentiation, hyperkeratinization, elastosis, collagen breakdown, and other histological changes in the stratum corneum, dermis, epidermis, the skin vascular system (e.g., telangiectasia or spider vessels), and underlying tissues (e.g., fat and / or muscle), especially those proximate to the skin. In certain embodiments, skin aging may be influenced by factors including hormonal status and climatic, working, social, and cultural conditions. The effects of aging on the skin are influenced by both intrinsic and extrinsic factors. Similar to other organs, the human skin undergoes progressive functional decline due to the accumulation of molecular damage. Oxidative stress and molecular damage contribute to both intrinsic aging, also called chronological aging and aging as a consequence of environmental factors, also called extrinsic aging. In certain embodiments, the skin aging is a result of extrinsic factors, such as smoking, excessive alcohol, and poor nutrition. In certain embodiments, the skin aging is a result of exposure to UV radiation (e.g., from UV radiation from sunlight).
[0236] In certain embodiments, the skin aging is a result of exposure to poor air quality (e.g., air pollution, including air polluted with particulate matter, soot, and nitrogen dioxide). As a consequence, aged skin exhibits many differences in comparison to youthful skin and also has a marked susceptibility to dermatologic disorders due to the structural and physiologic changes that occur with time.
[0237] In certain embodiments, the skin aging may be a result of or influenced by a skin disease. In certain such embodiments, the skin disease is atopic dermatitis, seborrheic dermatitis, seborrheic keratosis, epidermolysis bullosa acquisita, psoriasis, ichthyosis, cutaneous lupus erythematosus, dermatomyositis, scleroderma, chronic acne, chronic cellulites, pruritus and abnormal or defective scar formation in diabetes and premature aging diseases.
[0238] In other embodiments, the skin disease comprises dysplasias, actinic keratosis, basal cell carcinoma, squamous cell carcinoma, melanoma.
[0239] In certain embodiments, the skin aging may be the result of or influenced by a premature aging disease. In certain such embodiments, the premature aging disease is Hutchinson-Gilford Progeria syndrome (HGPS), Atypical progeria syndromes (APS), Mondibuloacral dysplasia (MAD), Werner syndrome (WS), Bloom syndrome (BS), Rothmund-Thomson syndrome (RTS), Cockayne syndrome (CS), Xeroderma Pigmentosum (XP), Trichothiodystrophy (TTD), Fanconi Anemia (FA), Ataxia telangiectasia (AT) and dyskeratosis congenita (DC).
[0240] A method of making a sunscreen composition is also disclosed. The method comprises heating an oil mixture comprising 5-10 wt % of a UV booster, 10-20 wt % of an emollient, and 5-15 wt % of an emulsifier to 75 °C and mixing the oil mixture until the oil mixture becomes homogeneous; mixing an aqueous solution comprising 0.2-0.6 wt % of a disodium EDTA and 55°C deionized water; adding 2-7 wt % of a glycerin, 0.1-0.5 wt % of a xanthan gum, 30-35 wt % of zinc oxide dispersion, 0.01-0.4 wt % of xanthommatin, 5-10 wt % of an antioxidant carrier, and 0.1-0.5 wt % of a pH adjuster to the aqueous solution; mixing the oil mixture and the aqueous solution; and adding 0.5-2.0 wt % a preservative.
[0241] In some embodiments, the UV-filter booster is butyl octyl salicylate.
[0242] In some embodiments, the emollient is cetearyl nonanoate, capyrylic / capric triglyceride, sunflower seed oil, vegetable oil, simmondsia chinensis (jojoba) seed oil, and curcuma longa (Turmeric) root extract. In some embodiments, the emulsifier is selected from polysorbate 20, sorbitan olivate, glyceryl stearate SE, polyglyceryl-6 pentaoleate, and glyceryl oleate.
[0243] In some embodiments, the pH adjuster is sodium hydroxide.
[0244] In some embodiments, the preservative is phenoxyethanol and ethylhexylglycerin.
[0245] In some embodiments, the antioxidant carrier comprises propanediol and lecithin. The foregoing is merely illustrative of the principles of the disclosure, and the apparatuses can be practiced by other than the described implementations, which are presented for purposes of illustration and not of limitation. Variations and modifications will occur to those of skill in the art after reviewing this disclosure. The disclosed features may be implemented, in any combination and subcombination (including multiple dependent combinations and subcombinations), with one or more other features described herein. The various features described or illustrated above, including any components thereof, may be combined or integrated in other systems, composition, and formulations. Moreover, certain features may be omitted or not implemented.
[0246] Examples of changes, substitutions, and alterations are ascertainable by one skilled in the art and could be made without departing from the scope of the information disclosed herein. All references cited herein are incorporated by reference in their entirety and made part of this application.
[0247] Exemplification
[0248] The invention now being generally described, it will be more readily understood by reference to the following examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention.
[0249] Example 1 : Preparation of Liposome Encapsulated Xanthommatin
[0250] Table 1: Formulation 1.
[0251] Part A: Water was heated to 75°C with stirring. Xanthommatin (i.e., ammonium xanthommatin) was slowly sprinkled in and allowed to mix until the majority of the Xanthommatin had dissolved into solution. Once the Xanthommatin had dissolved into solution, the solution was removed from heat, placed into an ice bath, and cooled to 40°C. Part B: Once Phase A reached 40°C, the solution was allowed to continue to stir before adding in the self-assembling liposome to generate the encapsulated product.
[0252] Table 2: Formulation 2.
[0253] This formulation of Xa-liposomes use less water when compared to formulation 1.
[0254] Part A: Water was heated to 75°C with stirring. Xanthommatin (i.e., ammonium xanthommatin) was slowly sprinkled in and allowed to mix for 15 minutes to dissolve Xanthommatin into solution.
[0255] Part B: Once the Xanthommatin had dissolved into solution, the Phase A solution was cooled to less than 60°C. Phase B was added slowly until pH reached 6-8. The pH was checked consistently between additions of NaOH and care was taken not to exceed a pH of 8. The solution was mixed for 15 minutes for uniform distribution and to ensure complete dissolution of Xanthommatin.
[0256] Part C: The main phase was added to a separate beaker with Phase C. This was stirred at 800-1000 rpm for 15-30 minutes without until a homogenous yellow colored liposomes were formed.
[0257] Example 2: Preparation of Liposome Encapsulated Xanthommatin
[0258] The phenoxazone and / or phenoxazine compound, or a salt thereof, (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin) can also be encapsulated in the liposome using a dehydration / hydration process. For example, the organic lipid can be emulsified in the aqueous phase with the phenoxazone and / or phenoxazine compound, or a salt thereof, (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin). Next, the organic phase can be removed by evaporation and water readded to form the phenoxazone and / or phenoxazine compound, or a salt thereof, (e.g., xanthommatin, or a salt thereof, such as ammonium xanthommatin) encapsulated within the liposome.
[0259] Example 3 : Spectrophotometric Analysis of Liposome Encapsulated Xanthommatin Xanthommatin alone, liposome alone, and ammonium xanthommatin encapsulated in a liposome (as prepared in Example 2) were each evaluated in a spectrophotometer to measure absorbance over the UV-visible range.
[0260] FIG. 1 demonstrates that when xanthommatin is encapsulated within a liposome (i.e., a nanoparticle), it provides a higher optical density “OD” (also referred to as intensity of absorbed light). These results show that using xanthommatin in particle form boosts UV absorbance. The increase in “OD” associated with the encapsulated product further suggests that ammonium xanthommatin (Xa) has been successfully encapsulated.
[0261] It is also demonstrated that encapsulation of xanthommatin in a liposome increases absorption of the liposomes in UV by about 35%, as shown in FIG. 2A. Results from FIG. 2B also shows that inclusion of liposomes increases absorption of xanthommatin in UV by about 20%.
[0262] Example 3 : Xanthommatin as an Antioxidant
[0263] The following formulations were prepared in order to validate Xanthommatin (Xa) as an antioxidant. The formulations comprise a zinc oxide dispersion as the mineral sunscreen. The zinc oxide dispersion contains zinc oxide particles in a dispersion containing caprylic / capric triglyceride, polyhydroxystearic acid and stearoyl glutamic acid.
[0264] Table 3: Formulation 3 (0.05% Xa).
[0265] Part A: Combine all phase A ingredients and heat to 75°C. Mix until homogenous, for at least 20 min at high speed to emulsify, and homogenize for 3 minutes. Continue mixing. Cool to 50°C while mixing and preparing Part B. Part B: In a separate beaker, heat water to 55°C. Dissolve EDTA into water. Create a slurry of glycerin and xanthan gum in a separate beaker, then add to water phase. Mix phase B until uniform, then add to phase A.
[0266] Part C: Mix main phase for 30 minutes, then homogenize for 3 minutes.
[0267] Part D: Begin cooling mixture while mixing. When <40°C, add phase C and mix until uniform. Cool to room temperature.
[0268] Based on a user-defined method of analysis, the SPF of Formulation 3 was monitored and recorded as 34 ± 17, indicating that this combination of materials could provide an SPF >30, as shown in FIG. 3.
[0269] Table 4: Formulation 4 (Control-no Xa, only liposomes and ZnO).
[0270] Part A: Combine all phase A ingredients and heat to 75°C. Mix until homogenous, for at least 20 min at high speed to emulsify, and homogenize for 3 minutes. Continue mixing. Cool to 50°C while mixing and preparing Part B. Part B: In a separate beaker, heat water to 55°C. Dissolve EDTA into water. Create a slurry of glycerin and xanthan gum in a separate beaker, then add to water phase. Mix phase B until uniform, then add to phase A.
[0271] Part C: Mix main phase for 30 minutes, then homogenize for 3 minutes.
[0272] Part D: Begin cooling mixture while mixing. When <40°C, add phase C and mix until uniform. Cool to room temperature.
[0273] Table 5: Formulation 5 (1 w / w % Xa with Liposomes and ZnO).
[0274] Part A: Combine all phase A ingredients and heat to 75°C. Mix until homogenous, for at least 20 min at high speed to emulsify, and homogenize for 3 minutes. Continue mixing. Cool to 50°C while mixing and preparing Part B. Part B: In a separate beaker, heat water to 55°C. Dissolve EDTA into water. Create a slurry of glycerin and xanthan gum in a separate beaker, then add to water phase. Mix phase B until uniform, then add to phase A.
[0275] Part C: Mix main phase for 30 minutes, then homogenize for 3 minutes. Part D: Begin cooling mixture while mixing. When <40°C, add phase C and mix until uniform. Cool to room temperature.
[0276] Table 6: Formulation 6 (0.2 w / w % Xa with Liposomes and ZnO). Part A: Combine all phase A ingredients and heat to 75°C. Mix until homogenous, for at least 20 min at high speed to emulsify, and homogenize for 3 minutes. Continue mixing. Cool to 50°C while mixing and preparing Part B.
[0277] Part B: In a separate beaker, heat water to 55°C. Dissolve EDTA into water. Create a slurry of glycerin and xanthan gum in a separate beaker, then add to water phase. Add preprepared liposomes. Mix phase B until uniform, then add to phase A.
[0278] Part C: Mix main phase for 30 minutes, then homogenize for 3 minutes.
[0279] Part D: Begin cooling mixture while mixing. When <40°C, add phase C and mix until uniform. Cool to room temperature. This formulation can be applied liberally to skin or a sample plate 20 minutes prior to exposure to sun.
[0280] FIG. 4B is an image of Formulation 6 (0.2 w / w% xanthommatin encapsulated in liposomes and mineral sunscreen).
[0281] Table 7: Formulation 7 (Control Liposome-ZnO, without Xa).
[0282] Part A: Combine all phase A ingredients and heat to 75°C. Mix until homogenous, for at least 20 min at high speed to emulsify, and homogenize for 3 minutes. Continue mixing. Cool to 50°C while mixing and preparing Part B.
[0283] Part B: In a separate beaker, heat water to 55°C. Dissolve EDTA into water. Create a slurry of glycerin and xanthan gum in a separate beaker, then add to water phase. Mix phase B until uniform, then add to phase A.
[0284] Part C: Mix main phase for 30 minutes, then homogenize for 3 minutes.
[0285] Part D: Begin cooling mixture while mixing. When <40°C, add phase C and mix until uniform. Cool to room temperature.
[0286] This formulation can be applied liberally to skin or a sample plate 20 minutes prior to exposure to sun.
[0287] FIG. 4A is an image of Formulation 7 (Control liposome and mineral sunscreen, without xanthommatin).
[0288] This formulation can be applied liberally to skin or a sample plate 20 minutes prior to exposure to sun.
[0289] Example 4: Xanthommatin as a Sun Filter / Sun Screen
[0290] The following formulations were prepared with or without liposomes and with or without additional UV-filter boosters in order to validate that formulations comprising Xanthommatin (Xa) can be used as a sun filter / sun screen.
[0291] Table 8: Formulation 8 (1 w / w% xanthommatin encapsulated in liposomes, UV- filter boosters, and without mineral sunscreen).
[0292] Part A: Combine all phase A ingredients and heat to 75°C. Mix until homogenous, for at least 20 min at high speed to emulsify, and homogenize for 3 minutes. Continue mixing. Cool to 50°C while mixing and preparing Part B. Part B: In a separate beaker, heat water to 55°C. Dissolve EDTA into water. Create a slurry of glycerin and xanthan gum in a separate beaker, then add to water phase. Add preprepared liposomes. Mix phase B until uniform, then add to phase A.
[0293] Part C: Mix main phase for 30 minutes, then homogenize for 3 minutes.
[0294] Part D: Begin cooling mixture while mixing. When <40°C, add phase C and mix until uniform. Cool to room temperature.
[0295] This formulation can be applied liberally to skin or a sample plate 20 minutes prior to exposure to sun.
[0296] FIG. 4C is an image of Formulation 8 (1 w / w% xanthommatin encapsulated in liposomes and UV-filter boosters, without mineral sunscreen). Table 9: Formulation 9 (1 w / w% xanthommatin, UV-filter boosters, and without liposomes).
[0297] Part A: Combine all phase A ingredients and heat to 75°C. Mix until homogenous, for at least 20 min at high speed to emulsify, and homogenize for 3 minutes. Continue mixing. Cool to 50°C while mixing and preparing Part B
[0298] Part B: In a separate beaker, heat water to 60°C. Dissolve EDTA into water. Create a slurry of glycerin and xanthan gum in a separate beaker, then add to water phase. Add Xanthommatin, stir for ~10 minutes, then add pH adjuster to neutralize. Mix phase B until uniform, then add to phase A. Part C: Mix main phase for 30 minutes, then homogenize for 3 minutes.
[0299] Part D: Begin cooling mixture while mixing. When <40°C, add phase C and mix until uniform. Cool to room temperature.
[0300] This formulation can be applied liberally to skin or a sample plate 20 minutes prior to exposure to sun.
[0301] Table 10: Formulation 10 (xanthommatin, without UV-filter boosters, and without liposomes).
[0302] Part A: Combine all phase A ingredients and heat to 75°C. Mix until homogenous, for at least 20 min at high speed to emulsify, and homogenize for 3 minutes. Continue mixing. Cool to 50°C while mixing and preparing Part B.
[0303] Part B: In a separate beaker, heat water to 55°C. Mix phase B until uniform, then add to phase A.
[0304] Part C: Mix main phase for 30 minutes for 3 minutes. Begin cooling mixture while mixing. When <40°C, add phase C and mix until uniform. Cool to room temperature. This formulation can be applied liberally to skin or a sample plate 20 minutes prior to exposure to sun.
[0305] This formulation can be applied liberally to skin or a sample plate 20 minutes prior to exposure to sun. FIG. 4D is an image of Formulation 10 (2 w / w% xanthommatin, without UV-filter boosters, without liposomes).
[0306] Example 5: In Vitro Measurements
[0307] 5, 1 Determination of Critical Wavelength of Sunscreen Formulations
[0308] Method: A Labsphere UV 2000S Ultraviolet Transmittance Analyzer was used to determine spectral transmittance for each wavelength over the full UV spectrum ( 290-400 nm) at 1 nm intervals. Polymethyl methacrylate (PMMA) plates were used as a substrate, where sunscreens are applied to new, untreated and roughened plates at 0.75 mg / cm2. Prior to analysis, the sunscreen is allowed to dry for 15 min in the dark.
[0309] FIG. 5 evaluates the critical wavelength for test products according to broad spectrum testing method published in 21 CFR 201.327 (J). FIG. 5A depicts the in vitro FDA broad spectrum of various compositions. FIG. 5B depicts the in vitro sun protection factor (SPF) of various compositions.
[0310] A mean critical wavelength of 370 nm or greater is classified as broad spectrum (data presented in FIG. 5A). For the in vitro SPF analysis (FIG. 5B), a similar procedure disclosed in Example 6 was followed. Here, mean transmittance values were determined for each wavelength over the full UV spectrum across 5 areas, which was used to calculate SPF.
[0311] The data in FIG. 5 indicate that the formulations with XA>0.2% w / w with ZnO (32%) are capable of generating a critical wavelength of 370 nm. Furthermore, XA > 1% w / w with or without liposomes in the absence of ZnO can also generate a critical wavelength of or greater than 370 nm, indicating that xanthommatin (XA) can extend the critical wavelength of sunscreen compositions.
[0312] FIG. 6 shows the intensity (AU) of Formulation 6 (0.2 w / w% xanthommatin encapsulated in liposomes and mineral sunscreen) and Formulation 7 (Control liposome and mineral sunscreen, but no xanthommatin) at different wavelengths. The mineral sunscreen is a zinc oxide dispersion, wherein the zinc oxide particles are dispersed in caprylic / capric triglyceride, polyhydroxystearic acid and stearoyl glutamic acid (32% ZnO).
[0313] It is to be noted that presence of xanthommatin boosts absorption of Zinc oxide in Formulation 6 by 4.5%. Table 11 shows the critical wavelength and SPF of Formulations 6 and 7 respectively.
[0314] Table 11: In vitro Absorption of Formulations 6 and 7.
[0315] 5,2 Determination of Spectral Performance of Sunscreen Formulations
[0316] Method: A Labsphere UV 2000S Ultraviolet Transmittance Analyzer was used to determine spectral transmittance for each wavelength over the full UV spectrum ( 290-400 nm) at 1 nm intervals. These data show that the presence of XA liposomes increases the absorptive properties of ZnO based sunscreens supporting its UV boosting properties.
[0317] FIG. 7 shows the intensity (AU) of formulations at different wavelength. FIG. 7A shows the intensity of Formulation 8 (1 w / w% xanthommatin encapsulated in liposomes and UV- filter boosters, but without mineral sunscreen) at different wavelength. FIG. 7B shows the intensity of Formulation 10 (2 w / w% xanthommatin, but without UV-filter boosters or liposomes) at different wavelength.
[0318] It is to be noted that presence of UV-filter boosters in Formulation 8 increase UVB performance by 2x as shown in Fig. 7A. Fig. 7B shows that in the absence of minerals or UV- filter boosters, Formulation 10 provides a broad spectrum coverage across the UV-spectrum. Table 12 shows the critical wavelength and SPF of Formulations 8 and 10 respectively.
[0319] Table 12: In vitro Absorption of Formulations 8 and 10.
[0320] Example 6: In Vivo Measurements
[0321] The SPF and water resistance (WR) studies were done according to US FDA Final Rule (2011) (UVB Testing). In order to pass the WR test, the sample must not show any erythema (sun bum). Table 13 shows the SPF and WR testing of various formulations.
[0322] Table 13: SPF and WR Studies.
[0323] FIG. 8 shows the in vivo SPF measurements of various formulations in test subjects (n=3). The SPF was measured on human subjects. In this example, 3 subjects were tested for each of the formulation listed in Table 13. The results show that the presence of XA liposomes (>0.2% w / w) in mineral-based sunscreens offer an in vivo SPF of about 30. Without minerals, XA liposomes (>1% w / w) provide an SPF greater than 2.
[0324] Example 6: Xanthommatin based mineral sunscreens
[0325] Sunscreens containing 0.2% w / w XA (concentrations 5x lower than those used in the OECD guided ecotoxicological testing) with ZnO were formulated and evaluated for photoprotection (FIG. 9). In these W / O formulations, XA was processed and added as a liposome to the mineral sunscreens. The presence of the liposome not only aided in the emulsification between phases but also contributed to overall stability of the final formula, yielding a continuous phase after formulation (FIG. 9A). Of all concentrations tested during the pre-formulation stages, 0.2% w / w XA was the minimum concentration needed to observe any boosting effect. At concentrations lower than 0.2% / w / w, the overall effect of XA on the final sunscreen performance (i.e., UVAPF and critical wavelength) was not significant. When compared to the control (no XA) formula, the presence of the 0.2% XA appeared to increase the overall UV spectral performance by 4.5%, when the area under each curve was calculated and compared directly (FIG. 9B). These features also led to a higher critical wavelength of the XA-containing formula (371.01 compared to 368.86 nm for the control; FIG. 9C), despite a lower initial SPF measured in vitro, albeit still within the error of the control (26.6 ± 1.3 compared to 31.3 ± 2.8 for control; N= 3, FIG. 9D). This study demonstrates that the inclusion of 0.2% XA LIPO showed 1) enhanced broad spectrum coverage, 2) 97.78 % total UV stability after four hours irradiation, 3) no irritation or sensitization on skin, 4) strong UVA region protection, and 5) SPF ~30.
[0326] Example 7: Photostability study
[0327] The static SPF and UVAPF of the XA boosted mineral sunscreen on twenty human subjects (ten separate subjects per study) were measured. A mean SPF value of 31.45 ± 4.22 was measured across the participants (Table 14), and the mean UVAPF value was 10 (Table 15). The photostability of the formulas before and after exposure to a known dose of radiation equivalent to four hours of sun exposure (UV wavelengths only) in vitro was tested. From these data, 97.62% and 98.06% UVA and UVB absorbance stability were observed, respectively, suggesting that the formulas are photostable in the UV spectral range (Table 16). Assays with a human insult repeat patch test to determine whether irritation and sensitization (contact allergy) potential of the custom-designed Xa-boosted formula were elicited across 100 separate subjects. After a multi -week trial, no adverse reactions from the XA-containing sunscreens were noted. Table 14. The minimum erythemal dose (MED) and SPF values of the XA-containing mineral sunscreens measured on N=10 subjects. MEDIu represents the initial minimal erythemal dose (untreated), and MEDIIu is the unprotected site.
[0328] Table 15. UVAF values of the XA-containing mineral sunscreens measured on N=10 subjects.
[0329] Table 16. Photostability analysis of the XA-containing mineral sunscreens.
[0330] Example 8: White casting study
[0331] Two skin types were studied with a formulation of the present disclosure such as formulation X and a commercially available sunscreen from Neutrogena™ (without XA). 1 cm of each sunscreen was applied to skin and rubbed in until dry. Lightness was measured and the results are presented in FIG. 10. The formulation of the present disclosure offers better rub in and reduced lightness in skin color compared to the commercially available sunscreen.
[0332] Example 9: High energy visible light (HEV) and blue light blocking study Full HEV irradiation of 200 J / cm2was applied using a 1000-Watt solar simulator with an HEV filtered xenon arc lamp. PL756 spectroradiometer captured spectral transmittance which was used to calculate the mean critical wavelength, % blocking potential in HEV (400 - 500 nm) and blue light (415 - 455 nm). The results are presented in Table 17 below. Use of 0.2 % XA LIPO increased HEV and blue light protection by 45% and 46% compared to the control (no XA), respectively.
[0333] Table 17: High energy visible light (HEV) and blue light blocking results
[0334] Example 10: UV filter boosting properties of xanthommatin Results in FIG. 11 depict (A) the absorptive properties of varying concentrations of xanthommatin in DMSO. (B) Absorptive properties of xanthommatin compared directly to traditional UV filters at a fixed concentration (0.1- 0.2mM) where xanthommatin is at 0.6 mM in DMSO. (C) A comparison of the UVA (recorded at 360 nm) and UVB (recorded at 300 nm) absorbance of traditional UV filters alone, filters blended with xanthommatin (+0.6 mM), and xanthommatin only (0.6 mM) showing that the addition of xanthommatin contributes to the enhanced performance of traditional UV filters, eliciting broad spectrum protection against solar UV. Abbreviations used in FIG. 11 are as follows:
[0335] OXY: oxybenzone
[0336] OCTINOX: octinoxate
[0337] OCTOCRY: octocrylene
[0338] HOMOSAL: homosalate
[0339] OCTISAL: octisalate
[0340] A VO: avobenzone
[0341] Example 11 : Stability of formulations with xanthommatin
[0342] FIG. 12 shows that xanthommatin only in a mineral formulation destabilizes the formula. When xanthommatin is in a liposome and placed in the mineral formulation, the final formulation is stable. Data on FIG. 12 support the need for liposomes in sunscreens with xanthommatin and ZnO.
Claims
Claims1. A sunscreen composition comprising32 wt % of zinc oxide dispersion;0.2 wt % of xanthommatin;8.2 wt % of an antioxidant carrier;17 wt % of an emollient;12 wt % of an emulsifier;8 wt % of a UV booster;0.4 wt % of a chelating agent;4 wt % of a humectant;0.3 wt % of a thickener;0.18 wt % of a pH adjuster; and1.0 wt % of a preservative, wherein the antioxidant carrier comprises propanediol and lecithin.
2. The sunscreen composition of claim 1, wherein the chelating agent is disodium EDTA.
3. The sunscreen composition of claim 1 or 2, wherein the UV-filter booster is butyl octyl salicylate.
4. The sunscreen composition of any of claims 1-3, wherein the emollient is cetearyl nonanoate, capyrylic / capric triglyceride, sunflower seed oil, vegetable oil, simmondsia chinensis (jojoba) seed oil, and curcuma longa (Turmeric) root extract.
5. The sunscreen composition of any of claims 1-4, wherein the emulsifier is polysorbate 20, sorbitan olivate, glyceryl stearate SE, polyglyceryl-6 pentaoleate, and glyceryl oleate.
6. The sunscreen composition of any of claims 1-5, wherein the humectant is glycerin.
7. The sunscreen composition of any of claims 1-6, wherein the thickener is xanthum gum.
8. The sunscreen composition of any of claims 1-7, wherein the pH adjuster is sodium hydroxide.
9. The sunscreen composition of any of claims 1-8, wherein the preservative is phenoxyethanol and ethylhexylglycerin.
10. A sunscreen composition comprising: an oil mixture comprising UV booster, UV filter, emollient, and emulsifier; and an aqueous solution comprising diluent, chelating agent, humectant, thickener, antioxidant, antioxidant carrier, and pH adjuster, wherein the antioxidant is a phenoxazone or phenoxazine compound.
11. The sunscreen of claim 10, wherein the phenoxazone or phenoxazine compound is xanthommatin, decarboxylated xanthommatin, uncyclized xanthommatin, ommatin D, or dihydroxy-xanthommatin, rhodommatin.
12. The sunscreen composition of claim 10 or 11, wherein the phenoxazone or phenoxazine compound is xanthommatin.
13. The sunscreen composition of any of claims 10-12, wherein the antioxidant comprises 0.01-0.4 wt % of the sunscreen composition.
14. The sunscreen composition of any of claims 10-13, wherein the antioxidant comprises 0.2 wt % of the sunscreen composition.
15. The sunscreen composition of any of claims 10-14, wherein the UV filter is a zinc oxide dispersion or titanium dioxide.
16. The sunscreen composition of any of claims 10-15, wherein the UV filter is a zinc oxide dispersion.
17. The sunscreen composition of any of claims 10-16, wherein the UV filter comprises 25-40 wt % of the sunscreen composition.
18. The sunscreen composition of any of claims 10-17, wherein the UV filter comprises 30-35 wt % of the sunscreen composition.
19. The sunscreen composition of any of claims 10-18, wherein the UV filter comprises 32 wt % of the sunscreen composition.
20. The sunscreen composition of any of claims 10-19, wherein the antioxidant carrier comprises a phospholipid and a polyol.
21. The sunscreen composition of claim 20, wherein the phospholipid comprises one or more of egg yolk lecithin, soybean lecithin, sphingomyelin, hydrogenated or nonhydrogenated phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol, dimyristoylphosphatidylcholine (DMPC), distearoylphosphatidylcholine, palmitoyl-stearoylphosphatidylcholine, dipalmitoyl phosphatidylcholine, and hydrogenated lecithin.
22. The sunscreen composition of claim 20, wherein the phospholipid is lecithin.
23. The sunscreen composition of claim 20, wherein the polyol comprises one or more of propanediol, propylene glycol, dipropylene glycol, 1,3-butylene glycol, glycerin, methylpropanediol, isoprene glycol, pentylene glycol, erythritol, xylitol and sorbitol.
24. The sunscreen composition of claim 20, wherein the polyol comprises propanediol.
25. The sunscreen composition of any of claims 10-24, wherein the antioxidant carrier comprises propanediol and lecithin.
26. The sunscreen composition of any of claims 10-25, wherein the antioxidant carrier has less than 1000 nm in diameter.
27. The sunscreen composition of any of claims 10-26, wherein the antioxidant carrier has a mean diameter of 250 nm.
28. The sunscreen composition of any of claims 10-27, wherein the antioxidant carrier has from about 200 to about 400 nm in diameter.
29. The sunscreen composition of any of claims 10-28, wherein the antioxidant carrier comprises 1-10 wt % of the sunscreen composition.
30. The sunscreen composition of any of claims 10-29, wherein the antioxidant carrier comprises 5-10 wt % of the sunscreen composition.
31. The sunscreen composition of any of claims 10-30, wherein the antioxidant carrier comprises 8.2 wt % of the sunscreen composition.
32. The sunscreen composition of any of claims 10-31, wherein the chelating agent is di sodium EDTA.
33. The sunscreen composition of any of claims 10-32, wherein the chelating agent comprises 0.2-0.6 wt % of the sunscreen composition.
34. The sunscreen composition of any of claims 10-33, wherein the chelating agent comprises 0.4 wt % of the sunscreen composition.
35. The sunscreen composition of any of claims 10-34, wherein the UV-filter booster is butyl octyl salicylate.
36. The sunscreen composition of any of claims 10-35, wherein the UV-filter booster comprises 5-10 wt % of the sunscreen composition.
37. The sunscreen composition of any of claims 10-36, wherein the UV-filter booster comprises 8 wt % of the sunscreen composition.
38. The sunscreen composition of any of claims 10-37, wherein the emollient is cetearyl nonanoate, caprylic / capric triglyceride, sunflower seed oil, vegetable oil, Simmondsia Chinensis (jojoba) seed oil, Argania Spinosa (argan) oil, curcuma longa (turmeric) root extract, Aloe Barbadensis extract, cetearyl alcohol, cetearyl glucoside, glucose, (vegetable oil (and) Simmondsia Chinensis (jojoba) seed oil (and) turmeric root extract), or a combination thereof.
39. The sunscreen composition of any of claims 10-38, wherein the emollient is cetearyl nonanoate, capyrylic / capric triglyceride, sunflower seed oil, vegetable oil, simmondsia chinensis (jojoba) seed oil, and curcuma longa (Turmeric) root extract.
40. The sunscreen composition of any of claims 10-39, wherein the emollient comprises 10-20 wt % of the sunscreen composition.
41. The sunscreen composition of any of claims 10-40, wherein the emollient comprises 17 wt % of the sunscreen composition.
42. The sunscreen composition of any of claims 10-41, wherein the emulsifier is polysorbate 20, sorbitan olivate, glyceryl stearate SE, polyglyceryl-6 pentaoleate,glyceryl oleate, glyceryl oleate momomuls, olivem 900, oleamuls WO or a combination thereof.
43. The sunscreen composition of any of claims 10-42, wherein the emulsifier is polysorbate 20, sorbitan olivate, glyceryl stearate SE, polyglyceryl-6 pentaoleate, and glyceryl oleate.
44. The sunscreen composition of any of claims 10-43, wherein the emulsifier comprises 5-15 wt % of the sunscreen composition.
45. The sunscreen composition of any of claims 10-44, wherein the emulsifier comprises 12 wt % of the sunscreen composition.
46. The sunscreen composition of any of claims 10-45, wherein the diluent is deionized water.
47. The sunscreen composition of any of claims 10-46, wherein the diluent comprises 10- 20 wt % of the sunscreen composition.
48. The sunscreen composition of any of claims 10-47, wherein the diluent comprises 16.72 wt % of the sunscreen composition.
49. The sunscreen composition of any of claims 10-48, wherein the humectant is glycerin.
50. The sunscreen composition of any of claims 10-49, wherein the humectant comprises 2-7 wt % of the sunscreen composition.
51. The sunscreen composition of any of claims 10-50, wherein the humectant comprises 4 wt % of the sunscreen composition.
52. The sunscreen composition of any of claims 10-51, wherein the thickener is xanthum gum.
53. The sunscreen composition of any of claims 10-52, wherein the thickener comprises 0.1-0.5 wt % of the sunscreen composition.
54. The sunscreen composition of any of claims 10-53, wherein the thickener comprises 0.3 wt % of the sunscreen composition.
55. The sunscreen composition of any of claims 10-54, wherein the pH adjuster is sodium hydroxide.
56. The sunscreen composition of any of claims 10-55, wherein the pH adjuster comprises 0.1-0.5 wt % of the sunscreen composition.
57. The sunscreen composition of any of claims 10-56, wherein the pH adjuster comprises 0.18 wt % of the sunscreen composition.
58. The sunscreen composition of any of claims 10-57, further comprising a preservative.
59. The sunscreen composition of any of claims 10-58, wherein the preservative is phenoxyethanol and ethylhexylglycerin.
60. The sunscreen composition of any of claims 10-59, wherein the preservative comprises 0.5-2.0 wt % of the sunscreen composition.
61. The sunscreen composition of any of claims 10-60, wherein the preservative comprises 1.0 wt % of the sunscreen composition.
62. The sunscreen composition of any of claims 10-61, wherein the sunscreen composition blocks 30-60 % of a high energy visible light and blue light.
63. The sunscreen composition of any of claims 10-62, wherein the sunscreen composition blocks 40-50 % of a high energy visible light and blue light.
64. The sunscreen composition of any of claims 10-63, wherein the sunscreen composition blocks about 45 % of a high energy visible light and blue light.
65. The sunscreen composition of any of claims 10-64, wherein the sunscreen composition has a Sun Protection Factor (SPF) from about 15 to about 50.
66. A method of making a sunscreen composition, comprising: heating an oil mixture comprising 5-10 wt % of a UV booster, 10-20 wt % of an emollient, and 5-15 wt % of an emulsifier to 75°C and mixing the oil mixture until the oil mixture becomes homogeneous; mixing an aqueous solution comprising 0.2-0.6 wt % of a disodium EDTA and 55°C deionized water;adding 2-7 wt % of a glycerin, 0.1-0.5 wt % of a xanthan gum, 30-35 wt % of zinc oxide dispersion, 0.01-0.4 wt % of xanthommatin, 5-10 wt % of an antioxidant carrier, and 0.1-0.5 wt % of a pH adjuster to the aqueous solution; mixing the oil mixture and the aqueous solution; and adding 0.5-2.0 wt % a preservative.
67. The method of claim 66, wherein the UV-filter booster is butyl octyl salicylate.
68. The method of claim 66 or 67, wherein the emollient is cetearyl nonanoate, capyrylic / capric triglyceride, sunflower seed oil, vegetable oil, simmondsia chinensis (jojoba) seed oil, and curcuma longa (Turmeric) root extract.
69. The method of any of claims 65-68, wherein the emulsifier is selected from polysorbate 20, sorbitan olivate, glyceryl stearate SE, polyglyceryl-6 pentaoleate, and glyceryl oleate.
70. The method of any of claims 65-69, wherein the pH adjuster is sodium hydroxide.
71. The method of any of claims 65-70, wherein the preservative is phenoxyethanol and ethylhexylglycerin.
72. The method of any of claims 65-71, wherein the antioxidant carrier comprises propanediol and lecithin.
73. A cosmetic composition comprising a zwitterionic small molecule of molecular weight ranging from 150-600 Da encapsulated in a liposome.
74. The cosmetic composition of claim 73, wherein the zwitterionic small molecule comprises a phenoxazone and / or phenoxazine compound, or a salt thereof.
75. The cosmetic composition of claim 74, wherein the phenoxazone and / or phenoxazine compound, or a salt thereof, is selected from xanthommatin, decarboxylated xanthommatin, uncyclized xanthommatin, ommatin D, dihydroxy -xanthommatin, rhodommatin, a derivative of any of the foregoing, a precursor of any of the foregoing, and salts of any of the foregoing.
76. The cosmetic composition of claim 74 or 75, wherein the phenoxazone and / or phenoxazine compound, or a salt thereof, comprises unaggregated molecules.
77. The cosmetic composition of any of claims 74-76, wherein the phenoxazone and / or phenoxazine compound, or a salt thereof, is xanthommatin, or a salt thereof.
78. The cosmetic composition of claim 77, wherein the phenoxazone and / or phenoxazine compound, or a salt thereof, is ammonium xanthommatin.
79. The cosmetic composition of any of claims 74-78, wherein the phenoxazone and / or phenoxazine compound, or a salt thereof, comprises 0.01-5 wt % of the composition.
80. The cosmetic composition of claim 79, wherein the phenoxazone and / or phenoxazine compound, or a salt thereof, comprises 0.01-1 wt % of the composition.
81. The cosmetic composition of claim 80, wherein the phenoxazone and / or phenoxazine compound, or a salt thereof, comprises 0.01-0.4 wt % of the composition.
82. The cosmetic composition of claim 80, wherein the phenoxazone and / or phenoxazine compound, or a salt thereof is formulated as an antioxidant.
83. The cosmetic composition of any of claims 73-82, wherein the said composition comprises a sunscreen, wherein the sunscreen is a mineral sunscreen or a chemical sunscreen.
84. The cosmetic composition of claim 83, wherein the mineral sunscreen is selected from a zinc oxide dispersion, titanium dioxide, or mixtures thereof, and wherein the chemical sunscreen is selected from avobenzone, oxybenzone, oxybenzone cinoxate, homosalate, octisalate, octinoxate, octocrylene, and / or trolamine salicylate.
85. The cosmetic composition of claim 84, wherein the mineral sunscreen is a zinc oxide dispersion, wherein the zinc oxide dispersion comprises zinc oxide particles dispersed in caprylic / capric triglyceride, polyhydroxystearic acid and stearoyl glutamic acid.
86. The cosmetic composition of claim 84, wherein the mineral sunscreen is titanium dioxide.
87. The cosmetic composition of claim 85, wherein the cosmetic composition is formulated so that the mineral sunscreen does not leave a white cast when applied directly to the skin.
88. The cosmetic composition of any of claims 73-87, wherein the liposome comprises a phospholipid and a polyol.
89. The cosmetic composition of claim 88, wherein the phospholipid is selected from natural phospholipids, fatty acids and synthetic phospholipids.
90. The cosmetic composition of claim 88, wherein the phospholipid comprises one or more of egg yolk lecithin, soybean lecithin, sphingomyelin, hydrogenated or non-hydrogenated phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol, dimyristoylphosphatidylcholine (DMPC), distearoylphosphatidylcholine, palmitoyl-stearoylphosphatidylcholine, dipalmitoyl phosphatidylcholine, and hydrogenated lecithin.
91. he cosmetic composition of claim 88, wherein the phospholipid comprises lecithin.
92. The cosmetic composition of claim 91, wherein the lecithin is a naturally derived unsaturated or saturated lecithin extracted from soybean or egg yolk.
93. The cosmetic composition of any of claims 82-92, wherein the polyol comprises one or more of propanediol, propylene glycol, dipropylene glycol, 1,3 -butylene glycol, glycerin, methylpropanediol, isoprene glycol, pentylene glycol, erythritol, xylitol and sorbitol.
94. The cosmetic composition of claim 93, wherein the polyol comprises propanediol.
95. The cosmetic composition of any of claims 73-94, wherein the liposomes are less than 1000 nm in diameter.
96. The cosmetic composition of any of claims 73-95, wherein the liposomes have a mean diameter of 250 nm.
97. The cosmetic composition of any of claims 73-96, wherein the liposomes are from about 200 to about 400 nm in diameter.
98. The cosmetic composition of any of claims 73-97, wherein the liposomes have a pH of about 5 to about 8.
99. The cosmetic composition of any of claims 73-98, wherein the composition is a water- in-oil emulsion.
100. The cosmetic composition of any of claims 73-99, wherein the liposomes comprise 1- 5 wt % of the composition.
101. The cosmetic composition of claim 100, wherein the liposomes comprise 2-4 wt % of the composition.
102. The cosmetic composition of claim 100, wherein the liposomes comprise 3 wt % of the composition.
103. The cosmetic composition of any of claims 80-102, wherein the said composition has a pH from about 6.8 to about 7.4.
104. The cosmetic composition of any of claims 80-103, wherein the said composition has a Sun Protection Factor (SPF) from about 15 to about 45.
105. The cosmetic composition of any of claims 80-104, wherein the composition is formulated as a lotion, mousse, or a cream.
106. A cosmetic composition formulated as a sunscreen with a UV filtering material comprising phenoxazone and / or phenoxazine compound, or a salt thereof, wherein the phenoxazone and / or phenoxazine compound, or a salt thereof is optionally xanthommatin, decarboxylated xanthommatin, uncyclized xanthommatin, ommatin D, dihydroxy- xanthommatin, rhodommatin, a derivative of any of the foregoing, a precursor of any of the foregoing, and salts of any of the foregoing., wherein the phenoxazone and / or phenoxazine compound, or a salt thereof comprise at least 1 wt % or higher of the cosmetic composition.
107. The cosmetic composition of claim 106, wherein the phenoxazone and / or phenoxazine compound, or a salt thereof is xanthommatin or a salt thereof, wherein the xanthommatin or a salt thereof is ammonium xanthommatin.
108. The cosmetic composition of claim 106, wherein the xanthommatin or a salt thereof comprise from about 1 wt % to about 5 wt % of the composition.
109. The cosmetic composition of any of claims 106-108, wherein said composition has a pH from about 6.7 to about 8.0.
110. The cosmetic composition of any of claims 106-109, wherein said composition has a Sun Protection Factor (SPF) from about 15 to about 50.
111. The cosmetic composition of any of claims 106-110, wherein the composition is formulated as a cream, mousse, or spray.
112. The cosmetic composition of any of claims 106-111, wherein the composition is waterbased or a water-in-oil emulsion.
113. The cosmetic composition of any of claims 106-112, wherein the composition may optionally comprise a liposome.
114. The cosmetic composition of claim 113, wherein the liposome comprises a phospholipid and a polyol.
115. The cosmetic composition of claim 114, wherein the phospholipid is selected from natural phospholipids, fatty acids and synthetic phospholipids.
116. The cosmetic composition of claim 114, wherein the phospholipid comprises one or more of egg yolk lecithin, soybean lecithin, sphingomyelin, hydrogenated or non-hydrogenated phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol, dimyristoylphosphatidylcholine (DMPC), distearoylphosphatidylcholine, palmitoyl-stearoylphosphatidylcholine, dipalmitoyl phosphatidylcholine, and hydrogenated lecithin.
117. The cosmetic composition of claim 114, wherein the phospholipid comprises lecithin.
118. The cosmetic composition of claim 117, wherein the lecithin is a naturally derived unsaturated or saturated lecithin extracted from soybean or egg yolk.
119. The cosmetic composition of any of claims 114-118, wherein the polyol comprises one or more of propanediol, propylene glycol, dipropylene glycol, 1,3 -butylene glycol, glycerin, methylpropanediol, isoprene glycol, pentylene glycol, erythritol, xylitol and sorbitol.
120. The cosmetic composition of claim 119, wherein the polyol comprises propanediol.
121. The cosmetic composition of any of claims 113-120, wherein the liposomes are less than 1000 nm in diameter.
122. The cosmetic composition of any of claims 113-121, wherein the liposomes have a mean diameter of 250 nm.
123. The cosmetic composition of any of claims 113-122, wherein the liposomes are from about 200 to about 400 nm in diameter.
124. The cosmetic composition of any of claims 113-123, wherein the liposomes have a pH of about 5 to about 8.
125. The cosmetic composition any of claims 113-124, wherein the liposomes comprise 1-5 wt % of the composition.
126. The cosmetic composition of claim 125, wherein the liposomes comprise 2-4 wt % of the composition.
127. The cosmetic composition of claim 125, wherein the liposomes comprise 3 wt % of the composition.
128. The cosmetic composition of any of claims 80-125, further comprise one or more UV- filter booster, one or more emollient, one or more emulsifier, diluent, humectant, thickener, pH adjuster and preservative.
129. The cosmetic composition any of claims 106-127, further comprise one or more emollient, one or more emulsifier, diluent, humectant, thickener, pH adjuster and preservative.
130. The cosmetic composition any of claims 80-127, optionally comprising a chelating agent.
131. The cosmetic composition of claim 130, wherein the chelating agent is disodium EDTA.
132. The cosmetic composition any of claims 106-127, optionally compromising one or more UV-filter booster.
133. The cosmetic composition of claim 128 or claim 132, wherein the one or more UV- filter booster is selected from (vegetable oil (and) Simmondsia Chinensis (jojoba) seed oil (and) turmeric root extract), butyl octyl salicylate, or a combination thereof.
134. The cosmetic composition of claim 128 or claim 129, wherein the one or more emollient is selected from cetearyl nonanoate, caprylic / capric triglyceride, sunflower seed oil, vegetable oil, Simmondsia Chinensis (jojoba) seed oil, Argania Spinosa (argan) oil, curcuma longa (turmeric) root extract, Aloe Barbadensis extract, cetearyl alcohol, cetearyl glucoside, glucose, (vegetable oil (and) Simmondsia Chinensis (jojoba) seed oil (and) turmeric root extract), or a combination thereof.
135. The cosmetic composition of claim 128 or claim 129, wherein the one or more emulsifier is selected from polysorbate 20, sorbitan olivate, glyceryl stearate SE, polyglyceryl- 6 pentaoleate, glyceryl oleate, glyceryl oleate momomuls, olivem 900, oleamuls WO or a combination thereof.
136. The cosmetic composition of claim 128 or claim 129, wherein the diluent is deionized water.
137. The cosmetic composition of claim 128 or claim 129, wherein the humectant is glycerin.
138. The cosmetic composition of claim 128 or claim 129, wherein the thickener is xanthum gum.
139. The cosmetic composition of claim 128 or claim 129, wherein the preservative is phenoxyethanol (and) ethylhexylglycerin.
140. The cosmetic composition of claim 128 or claim 129, wherein the pH adjuster is sodium hydroxide.
141. A method of providing a sunscreen effect or an effect on one or more indications of skin-aging, comprising applying to a region of skin a cosmetic composition according to any one of claims 73-140.
142. The method of claim 141, wherein the said composition is applied directly to the region skin.
143. The method of claim 142, wherein the said composition is applied to the region of skin using a solid support.
144. The method of claim 143, wherein the solid support comprises a microfiber based substrate.
145. The method of claim 144, wherein the said composition is embedded within the microfiber based substrate.
146. The method of claim 143, wherein the solid support is a spray or an anhydrous material.
147. The method of any of claims 141-146, wherein the effect on one or more signs of skinaging comprises repairing or restoring skin elasticity or firmness in the region of skin.
148. The method of claim 147, wherein the repairing or restoring skin elasticity or firmness comprises stimulating elastin production, stimulating collagen production, and / or stimulating keratin growth in the region of skin.
149. The method of claim 148, wherein the repairing or restoring skin elasticity or firmness comprises stimulating collagen production and / or stimulating keratin growth in the region of skin.
150. The method of any of claims 141-149, wherein the effect on one or more signs of skinaging comprises reducing, preventing, or slowing collagen degradation in the region of skin.
151. The method of any of claims 141-150, wherein the effect on one or more signs of skin- aging comprises reduction, prevention, or slowing the appearance of hyperpigmentation in the region of skin.
Citation Information
Patent Citations
Photoprotective cosmetic compositions comprising xanthommatin as an antioxidant and UV-filter stabilizer
WO2022081942A1
Anti-aging cosmetic compositions comprising xanthommatin
WO2023009502A1
